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ABSTRACT
The recent finding that urine is not sterile raises a lot of questions: first and
foremost, what microorganisms are present, and are these microorganisms correlated with
clinical urinary symptoms? Recent work on the female urinary microbiota (FUM) found
that the communities of microorganisms differ between women with no lower urinary tract
symptoms (LUTS) and those with Urgency Urinary Incontinence (UUI) a form of overactive bladder syndrome. Specifically, a diverse or dysbiotic urinary microbiota was found
to be associated with symptomatic women. This suggests the possibility that the FUM can
be contributing to urinary symptoms. Conversely, it could also suggest that the FUM is
simply a result of the physical environment of the urogenital tract and plays no active role
in health. I hypothesize that the FUM is influencing LUTS, both as causative and
preventative agents towards the clinical urinary symptoms. To test this, I first looked at
the FUM of women with other urinary disorders: Stress Urinary Incontinence (SUI) and
women with urinary tract infection (UTI)-like symptoms. Since many common urinary
disorders share significant symptom overlap, I also assessed how the FUM correlates to
individual symptoms. These data support the hypothesis that these microorganisms are
able to influence LUTS. One specific organisms of the FUM, Lactobacillus crispatus, is
able to exert a beneficial effect on LUTS, by inhibiting the growth and colonization of
Uropathogenic Escherichia coli (UPEC), the most common cause of UTIs. The next step

xii

is to assess these potential interactions in an in vivo setting.

With that collective

knowledge, LUTS and UTI’s can be clinically treated with better effectiveness.
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CHAPTER I
INTRODUCTION
A History of the Urinary Microbiome & Microbiota
Microorganisms resident in and on the human body have long been overlooked with respect
to their ability to influence human health. A recent effort, through the Human Microbiome
Project, has attempted to shed some light on this subject by cataloging the microbial
composition of select anatomical sites of the human body, including the gastrointestinal
tract, the skin, the respiratory tract, and the vagina (Turnbaugh et al., 2007). This work was
done largely through the use of 16S rRNA gene sequencing, which identifies microbial
communities based on genomic DNA. This approach, however, has several limitations.
The process of sequencing may create biases depending on the specific primers used,
causing some taxonomic groups to be largely overlooked and others to be overrepresented.
Also, the data are not readily quantifiable. But most importantly, it is unclear whether the
identified microorganisms are actually viable. Unfortunately, this problem is exacerbated
by the fact that the majority of microorganisms are not cultivatable using today’s methods.
Indeed, several body sites were inadvertently ignored with respect to their microbial
composition due to outdated culture information. One of these sites is the bladder.
The long-standing belief that urine is sterile resulted in the Human Microbiome
Project overlooking the bladder. Clinical urinary dogma relates the presence of any bacteria
1
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with an inflammatory response to a urinary tract infection (UTI), while bacteria found in
the absence of inflammation or clinical symptoms are termed asymptomatic bacteriuria
(ABU). Since the 1950’s, the clinical practice for detection of infection in the bladder has
been based on the threshold of greater than or equal to 105 colony forming units per mL
urine (CFU/mL) of a bacterial uropathogen present in mid-stream urine. However, this
threshold of ≥105 CFU/mL was original intended to be used to detect kidney infection or
pyelonephritis (Kass, 1956). The idea was to screen a patient for pyelonephritis with this
assay before initiating kidney surgery to prevent post-operative sepsis (Kass, 1956, Kass,
1957). This threshold was later equated to all urinary infections and the assay is still used
today as the method of detection for lower urinary tract infections. Several studies over the
past 30 years have provided evidence that this threshold level is insufficient for the
detection of clinical UTIs (Stamm et al., 1982, Lipsky et al., 1987, Maskell, 2010, Khasriya
et al., 2013). There have even been efforts to assert that urine is not sterile in the absence
of clinically relevant infection (for a review, see Maskell, 2010). In more recent years, the
push has become even stronger to both re-evaluate this long standing belief and to change
urine cultivation protocols (Hooton et al., 2013).
There is now mounting concrete scientific evidence to verify the claim the urine
isn’t actually sterile. Evidence from both DNA sequencing and culture indicate the
presence of urinary microbial communities in urine samples obtained by voided midstream,
transurethral catheter and suprapubic aspirate methods (Siddiqui et al., 2011, Dong et al.,
2011, Fouts et al., 2012, Nelson et al., 2012, Wolfe et al., 2012, Lewis et al., 2013, Hilt et
al., 2014). 16S rRNA gene sequencing shows that a diverse group of bacteria reside in the
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urine of both men and women (Fouts et al., 2012, Nelson et al., 2012, Hilt et al., 2014).
This was identified through the comparisons of DNA sequences obtained from midstream
voided urine, transurethral catheter urine (TUC), and suprapubic aspirates (SPA) in women
with and without LUTS. These findings show that the DNA detected from voided urine
samples comes in part from the bladder (Wolfe et al., 2012). Use of an extended
quantitative urine culture (EQUC) protocol on TUC samples from women demonstrated
that a portion of the detected DNA comes from viable microorganisms that have been
overlooked by the use of the standard urine culture protocol (Hilt et al., 2014). Therefore,
female urinary microbiota (FUM) exist. Urinary microorganisms have also been found in
men after cultivation of centrifuged voided urine samples (Khasriya, et al., 2013, Nelson
et al., 2012, Dong et al., 2011). Thus, unique urinary microbiota (population of live
cultivatable microorganisms in a particular environment) and urinary microbiomes
(collective genetic material present in a particular environment) exist. Whether these
microorganisms represent a basal microflora of the bladder or are just transiently found
between various urogenital sites is unclear.
Interactions between the Urinary Microbiota & the Host
The urothelium is a stratified layer of epithelial cells lining the bladder wall. It is known
that several uropathogens (microorganisms known to be associated with inflammation and
symptoms) can associate with the urothelium (Coker et al., 2000, Struve et al., 2008). Some
organisms (e.g, Escherichia coli) can become intracellular with the use of type 1 fimbriae
(allows for attachment to uroplakin on the superficial layer of the urothelium), and form
intracellular bacterial communities that are resistant to antimicrobials and the host immune
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response (Anderson et al., 2003, Struve et al., 2008). Certain non-uropathogenic bacterial
species also are found associated with shed urothelial cells in voided urine (Khasriya et al.,
2013). Thus, it is expected that a large portion of the urinary microbiota exist attached to
the urothelium.
Because these urinary microorganisms are likely in direct contact with the host
cells, they could exert some influence on the host and vice versa. This is the case for many
known and well-studied uropathogens. This contact is primarily what drives the infection
and resulting symptoms of UTIs. Using uropathogenic Escherichia coli (UPEC) as an
example, there are a multitude of encoded virulence factors that enable bacteria to colonize
the urinary tract and persist (in both humans and mice). The presence of adhesins and
fimbriae on the bacterial cell surface allows UPEC to trigger host and bacterial signaling
pathways, deliver bacterial products into the host tissue, and promote bacterial invasion
and biofilm growth (Mulvey, 2002). Other surface-associated virulence factors include
lipopolysaccharide (LPS), which can trigger a proinflammatory immune response through
induction of nitric oxide and cytokine release (Backhed et al., 2001), as well as flagella,
which allow for more effective colonization and motility throughout the upper and lower
urinary tract (Pichon et al., 2009). Additionally, UPEC can produce several toxins that
result in inflammatory responses. α-haemolysin (HlyA) is a pore-forming lipoprotein that
acts on epithelial cells throughout the urinary tract (Bhakdi et al., 1986). Cytotoxic
necrotizing factor 1 (CNF1) is produced by several strains of pyelonephritic strains of
UPEC and helps facilitate intracellular invasion and protection against immune
phagocytosis (Rycke et al., 1999, Mills et al., 2000). TIR domain-containing protein (Tcp)
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allows for subversion of TLR signaling, permitting enhanced survival of the bacteria (Cirl,
et al., 2008). Conversely, diverse host defenses limit the colonization of UPEC. The low
pH and presence of salts, urea, and organic acids in the urine can all reduce UPEC survival
within the urinary tract (Sobel, 1997). The Tamm-Horsfall glycoprotein acts as an antiadhesive factor by binding the type 1 fimbriae of UPEC to prevent proper adherence to the
urothelium (Leeker et al., 1997). Bacterial cells that can bind to the urothelium and/or
invade, can be subjected to exfoliation of the superficial urothelial cells (Mysorekar et al.,
2002). Upon adherence to the urothelium, UPEC elicits an innate immune response
characterized by the local production of a number of proinflammatory cytokines and
chemokines, as well as apoptosis of the infected eukaryotic cells (Schilling, 2001). This
complex cross-talk between UPEC and the host is not unique to this microorganism; other
uropathogens behave similarly and evoke similar host responses. Whether these
characteristics apply to the entire urinary microbiota is unclear. It is probable that some
species of the microbiota communicate with the host in less harmful ways, which allows
them to persist as normal members of the bladder flora, similar to what occurs in the GI
tract. An additional layer of complexity to understanding the microbial interactions, exists
in that the microorganisms likely communicate with one another and this communication
can be either inter- or intra-species.
The Urinary Microbiota & Urinary Health
One piece of evidence that supports the claim that the non-uropathogens of the urinary
microbiota influence the host comes from Pearce et al. (2014). The authors of this
manuscript showed that the FUM is distinct in both composition and alpha-diversity
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between women with urgency urinary incontinence (UUI) and women without any LUTS
(Pearce et al., 2014).
LUTS refers to a group of urinary symptoms including filling or irritative
symptoms (frequency, urgency, dysuria, nocturia, and urinary incontinence) and voiding
or obstructive symptoms (hesitancy, weak stream, incomplete voiding, and urinary
retention) (Abrams, 2011). UUI is a form of over active bladder syndrome (OAB) that
encompasses the feelings of urgency with involuntary leakage (Stewart et al., 2003).
Current prevalence estimates for urinary incontinence in middle-aged and older women in
the general population range from 30-60% (Danforth et al., 2006). Treatment and therapies
for incontinence result in the spending of more than $20 billion per year in the United
States. The understood etiology of UUI is that of a neurological disorder resulting in
hyperactivity of the detrusor muscle surrounding the bladder (Michel et al., 2009).
However, treatment to block this misfiring is only successful in about 50-60% of
individuals (Santos et al., 2010). This knowledge, combined with the knowledge from
Pearce et al. (2014), suggests that an additional etiology of UUI, and possibly OAB, in
women, is the microbiota. One could imagine that the interplay between the bacteria and
the host tissue could result in downstream signaling events in the urothelial cells leading
to inappropriate detrusor muscle function. For example, human urothelial cells express
carnitine acetyltransferase (CarAT), an enzyme that catalyzes the synthesis of
acetylcholine (Le et al., 2014). Acetylcholine binds to the muscarinic receptors present on
the detrusor muscle activating muscle contraction. Therefore, if the FUM induces
upregulation of CarAT by the urothelium, then this shows that the microbiota can cause

7

UUI and OAB. If this is indeed the case, then it is possible that the FUM is involved in
several other urinary symptoms, as major or minor contributors.
Additional evidence in support of the possibility that the FUM contributes to
urinary health and symptoms comes from data showing that about 50% of women
experiencing UTI-like symptoms (frequency and urgency of urination, and dysuria) have
no detectable bacteria present by use of the standard urine culture (Najar et al., 2009, Franz
et al., 1999). Since EQUC is able to detect urinary microbiota in about 90% of urine
samples deemed, “no growth”, by the standard urine culture (Hilt et al., 2014), a majority
of the women experiencing UTI-like symptoms (despite a negative standard urine culture)
may have bacteria present. These microorganisms could be accounting for the urinary
symptoms. Therefore, using the techniques used in Hilt et al. (2013) and Pearce et al.
(2014), I will assess if the previously unidentified FUM is responsible for these symptoms.
Lactobacillus crispatus: An Overview
Lactobacillus is an abundant group of Gram-positive lactic acid-producing bacteria
commonly residing in the oral cavity, gastrointestinal (GI) tract, and the urogenital tract of
mammals. Many species of Lactobacilli are associated with food production due to their
preservative action (Bernardeau et al., 2006). Some Lactobacilli in the GI tract are
commonly considered to be probiotics because they confer a health benefit to the host
(Goldin et al., 1992). These benefits include prevention of intestinal infections, diarrhea,
and hypercholesterolemia, as well as maintenance of gut barrier function (Kailasapathy et
al., 2000). These probiotic bacteria exert their effects by activating both non-specific and
specific host immune responses (Gill, 1998, Kaila et al., 1992, Schiffrin et al., 1995). They
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also can alter the microbial balance of commensal enteric microorganisms (Kailasaparthy
et al., 2000). A similar protection is believed to occur in the healthy human vagina, where
colonization with Lactobacilli is correlated with the absence of numerous urogenital
conditions (Uehara et al., 2006, Stapleton et al., 2011, Hemmerling et al., 2009).
In many women, a healthy vagina is predominantly colonized by Lactobacillus.
Alternatively, some women may be prominently colonized by other anaerobes, but much
of these microorganisms also fall into the group of lactic acid-producing bacteria,
demonstrating an important role for lactic acid in this environment (Ravel et al., 2010).
Lactobacillus crispatus is one of four main species of Lactobacillus that tends to
dominate the vaginal microflora, where it can account for upwards of 80% of all vaginal
bacteria in a single individual (Ravel et al., 2010). L. crispatus contributes to the stability
of normal vaginal microbiota. Its absence is linked to a variety of vaginal abnormalities,
including BV (Fredricks et al., 2007). Interestingly, these highly supportive actions of L.
crispatus seem to be unique to this species, as other dominating Lactobacilli like L. gasseri
and L. iners, tend to be more conducive to the occurrence of abnormal vaginal microflora
as suggested by a longitudinal analysis in pregnant women (Verstraelen et al., 2009). In
regards to BV, it has been shown that L. crispatus can competitively exclude G. vaginalis,
promoting a healthy vaginal environment (Aroutcheva et al., 2001, Castro et al., 2013).
Not only can this occur through steric hindrance, but new data suggest that L. crispatus can
act to directly disrupt the pilus-mediated attachment process used by G. vaginalis to adhere
to the epithelium (Ojala et al., 2014). Additionally, certain strains of L. crispatus,
particularly strain CTV-05, are being tested as biotherapeutics for treatment of recurrent
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UTIs in women (Stapleton et al., 2011, Hemmerling et al., 2009, Antonio et al., 2009,
Kwok et al., 2006). The modest success of this strategy is likely due to the ability of L.
crispatus to inhibit uropathogenic E. coli (UPEC), the most common causative agent of
UTI, through the production of lactic acid and H2O2, competitive exclusion, and possibly
through targeted antimicrobial peptide production.
The genome sequences of ten L. crispatus strains are currently available (Nelson et
al., 2010, Salvetti et al., 2012). The genomes range in size from 2.0-2.7 Mb, and are
predicted to encode 2,022-2,643 proteins. Genome annotation data suggest that these
strains are able to produce lactic acid, H2O2, bacteriocins, and adhesion proteins, which
could be used in competitive adhesion to epithelial cells. Nine out of ten strains are vaginal
isolates; the one remaining strain is a chicken-isolated strain, ST1 (Nelson et al., 2010,
Ojala et al., 2010). Phylogenetic analysis of L. crispatus shows that this species shares the
most recent common ancestor with Lactobacillus helveticus and is also closely related to
Lactobacillus acidophilus. Among the L. crispatus cluster, the ST1 strain branches off first
from the vaginal isolates (Ojala et al., 2014, Kant et al., 2011).
Adhesion to tissue surfaces is necessary for long-term colonization and persistence.
In the vagina, strong adhesion to the epithelium by the commensal microbiota is protective
against pathogens through competitive exclusion. All ten strains of L. crispatus contain
several predicted adhesion proteins including mucus-binding and fibrinogen-binding
proteins (Ojala et al., 2014). L. crispatus strain ST1 was also recently found to produce a
Lactobacillus epithelium adhesion (LEA) protein that allows for binding to both chicken
crop epithelium and vaginal epithelial cells (Edelman et al., 2012). The adhesion provided
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by this protein and others allows ST1 to competitively exclude E. coli and Salmonella
(Edelman et al., 2003). L. crispatus also contains several putative S-layer proteins and
protein-encoding genes, some of which are involved in adhesion. S-layer proteins are
paracrystalline surface protein arrays commonly found in Lactobacillus and many other
bacteria and archaea. These proteins usually share very little homology. Typically, S-layer
proteins are around 45 kDa in size and consist of a moderately conserved C-terminus and
a strongly variable N-terminus (Sillanpaa et al., 2000). The function of these proteins can
vary from providing stability to the outer membrane, protection from bacteriophages,
resistance to pH, and adhesion (Sleytr et al., 1997). Many of the L. crispatus strains use
these S-layer proteins for binding to collagen (Toba et al., 1995, Sun et al., 2013). These
proteins may also be involved in the ability of L. crispatus to competitively exclude
pathogens (Chen et al., 2007). Additionally, L. crispatus is able to rapidly modify its
surface properties in response to changes in pH (Antikaninen et al., 2007).
L. crispatus strains contain several putative bacteriocin genes including ones
similar to enterolysin A, helveticin J, and pediocin (Ojala et al., 2014). Some strains also
contained genes for gassericin A, a bacteriocin commonly found in L. gasseri (Stoyacheva
et al., 2014). Recently, cervicovaginal lavage (CVL) from healthy women was shown to
contain proteins that are bactericidal towards E. coli. Several of these proteins correspond
to L. crispatus (Kalyoussef et al., 2012). Additionally, it is known that a L. crispatus
dominant vaginal microbiome correlates with an inhibitory effect against E. coli from
vaginal secretions (Ghartey et al., 2014). The bacteriocin, crispacin A, is produced by L.
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crispatus and shares sequence homology with other bacteriocins from lactic-acid bacteria,
but direct targets of this protein have not been identified (Tahara et al., 2006).
Thus, L. crispatus is clearly an important member of the commensal vaginal flora
and its probiotic characteristics have garnered much recent attention; however, the nature
of these characteristics remains poorly understood.

CHAPTER II
MATERIALS & METHODS
Patients and Sample Collection
Following Loyola institutional review board (IRB) approval for all phases of this project,
participants gave verbal and written consent for the collection and analysis of their urine
for research purposes. Participants were women with and without either subtype of urinary
incontinence (Chapter III) and women with and without UTI symptoms (Chapter IV).
Participants' symptoms were characterized with the Pelvic Floor Distress Inventory
(PFDI), a self-completed, validated symptom questionnaire (Due et al., 2013) (Chapter
III), or by a validated UTI Symptom Assessment (UTISA) questionnaire (Clayson et al.,
2005) (Chapter IV). All urinary incontinence participants were without clinical evidence
of UTI (i.e., standard urine culture negative and absence of clinical UTI diagnosis). Urine
was collected via transurethral catheterization from participants for the period December
2013 to May 2015 at the Female Pelvic Medicine and Reconstructive Surgery center of
Loyola University Medical Center. A portion of each urine sample was placed in a BD
Vacutainer Plus C&S Preservative Tube (Becton Dickinson and Co; Franklin Lakes, NJ)
and sent to the clinical microbiology laboratory for Standard Urine Culture. A separate
portion of the urine sample was placed at 4°C for no more than 4 h following collection, to
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be used for sequencing (Chapter III). To this portion, 10% AssayAssure (Thermo
Scientific; Waltham, MA) was added before freezing at −80°C.
Urine Culture Protocols
Standard & Modified Urine Culture.
The standard urine culture protocol involves the inoculation of 1 µL of urine onto
5% sheep blood agar (BAP) and MacConkey agar (BD BBL™ Prepared Plated Media,
Becton Dickinson and 94 Co; Sparks, MD) using a quantitative pinwheel streak. These
plates are incubated aerobically at 35°C for 24 hours (Table 1). This plating method
preferentially allows for the growth and quantification of rapidly growing Gram-negative
obligate aerobes at concentrations ≥103 CFU/mL. Most well-studied uropathogens will be
identified under these conditions.
The modified urine culture protocol is a revised version of the standard culture.
Instead of incubation under aerobic conditions, the BAP and MacConkey agar plates are
incubated in 5% CO2. Additionally, if no growth is detected at 24 hours, they are held in
the same conditions for a further 24 hours (Table 1). This plating method will allow for
the identification of slower growing microorganisms, including facultative anaerobes and
microaerophiles.
Standard culture is the typical method used by clinical microbiology laboratories
for the identification of UTIs. A positive urine culture, indicative of infection, is the growth
of any microorganism at ≥105 CFU/mL, though this threshold may vary based upon the
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patient population, type of urine specimen, and standard practice of the laboratory. The
modified culture was implemented by the clinical microbiology laboratory at Loyola
University Medical Center in December, 2014. All of the urine samples used in the later
described studies were also processed by the clinical microbiology laboratory staff. Thus,
data comparing the Extended Quantitative Urine Culture (EQUC) (see Extended
Quantitative Urine Culture) to routine culture may represent data from use of either the
Standard or Modified Cultures. These distinctions are indicated.
Extended Quantitative Urine Culture.
The EQUC protocol was used on TUC urine samples to identify the FUM (Hilt et
al., 2014). This protocol involves the inoculation of 100 µL of urine onto BAP, chocolate
agar, and colistin and nalidixic acid (CNA) agar (BD BBL™ Prepared Plated Media)
incubated in 5% CO2 at 35°C for 48 hours. Chocolate agar contains lysed red blood cells
and supports the growth of fastidious microorganisms. CNA agar is a selective medium for
Gram-positive bacteria. Additionally, 100 µL of urine is inoculated onto BAP and
incubated aerobically at 35°C for 48 hours. Finally, 100 µL of urine is inoculated onto
CDC anaerobe 5% sheep blood agar plate (BD BBL™ Prepared Plated Media) and
incubated under anaerobic conditions at 35°C for 48 hours (Table 1). All urine is plated
using a quantitative pinwheel streak. Collectively, this protocol will allow for the growth
and identification of rapid and slow growing Gram-negative and Gram-positive
microorganisms with a wide range of oxygen tolerances.
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Table 1. Summary of Urine Culture Protocols. The modified culture was implemented
at the Loyola University Medical Center Clinical Microbiology Laboratory on December
17, 2014.
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The expanded EQUC protocol is a modified version of the original EQUC. This
protocol uses two additional conditions: MacConkey agar, incubated aerobically at 35°C
for 48 hours and CDC anaerobe 5% sheep blood agar, incubated in a Campy gas mixture
(5% O2, 10% CO2, 85% N) at 35°C for 48 hours. The Campy condition provides an optimal
environment for the isolation of microaerophilic fecal microorganisms. Additionally, the
expanded EQUC uses three different volumes of urine: 1, 10, and 100 µL. Thus, a total of
21 plates are used for this protocol (Table 1).
Isolation, Identification, and Storage of Microorganisms
All morphologies and counts of colonies are recorded and documented for each individual
plate per culture protocol. Each unique morphology (per plate) is then sub-cultured to new
media and incubated in the appropriate conditions for 48 hours.
Once a pure culture is obtained, the microorganism is identified using Matrix
assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS).
This instrument uses mass spectrometry to analyze the bacterial proteins, allowing for
identification to the species level. A small portion of a single isolated colony is applied to
a 96-spot, polished, stainless steel target plate (Bruker Daltonik GmbH, Leipzig,
Germany). 1 µL of 70% formic acid is applied to each sample and allowed to dry at room
temperature. 1 µL of the matrix solution is then added to each sample and allowed to dry.
This solution is comprised of saturated α-cyano-4-hydrocinnamic acid (Bruker Daltonik)
in an organic solvent (High-Pressure Liquid Chromatography-Mass Spectrometry [HPLCMS]-grade water, 100% Trifluoroacetic Acid, and Acetonitrile; Fluka). The target plate is
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then placed in the MicroFlex LT mass spectrometer (Bruker Daltonik), and the results are
analyzed using MALDI Biotyper 3.0 software (Bruker Daltonik). A bacterial quality
control strain of DH5α Escherichia coli is included in each analysis. Each identification is
given a confidence score. A score between 2.000 and 3.000 is confident to the species level;
a score between 1.700 and 1.999 is confident to the genus level; a score below 1.700 is not
reliable. Samples with scores below 2.000 are repeated twice. If no confident score
(≥2.000) is obtained, the sample is re-sub-cultured for 48 hours and assessed by MALDITOF MS again. If still no confident score is obtained, the sample is not included in the data
analysis for that urine sample, and is Gram stained and classified as an “unknown”.
Each unique species per urine sample is inoculated into a vial of Brucella Broth
with 10% Glycerol (CryoSavers, Hardy Diagnostics) and stored at -80°C for future use.
A major limitation of these methods are that culture-based methods are biased by
the specific physiological conditions used. Though EQUC has been used with success (Hilt
et al., 2014, Pearce et al., 2014), it still has bias. Additionally, identification of unique
species based solely off of morphological characteristics may not always delineate species
accurately. Finally, MALDI-TOF MS can only identify a bacterial species if that bacterial
profile is already present in the computer database. Therefore, any unclassified or lessthan-confident classifications will remain unidentified and not included in any study
analyses in this thesis.
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Figure 1. Overview of the UTISA Questionnaire. The validated UTISA questionnaire
asks the participant to score the degree of severity and bother on a scale of 0-3 for seven
common UTI symptoms: Urgency of Urination, Frequency of Urination, Pain or Burning
when Passing Urine, Urinary Retention, Pressure in the Lower Abdomen or Pelvic Area,
Lower Back Pain, and Blood in the Urine. A score of 0 indicated no symptom present,
while a score of 3 indicated most severe/bothersome. On the left is a grouping of the seven
symptoms into four domains (Clayson et al., 2005).
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UTI Symptom Assessment Questionnaire
The UTI Symptom Assessment (UTISA) Questionnaire (Bayer Pharmaceuticals Corp.,
Global Health Economics and Outcomes, Research Department, West Haven CT. 2005) is
a validated questionnaire that is used to assess various common clinical symptoms of UTIs
(Clayson et al., 2005). This self-administered questionnaire asks the participant to rate the
degree of severity and bother on a scale of 0 to 3 for seven common UTI symptoms:
frequency of urination, urgency of urination, incomplete bladder emptying (urinary
retention), pain or burning during urination (dysuria), lower abdominal discomfort or
pain/pelvic pressure, lower back pain, and blood in the urine (hematuria). A score of 0
corresponds to no symptom present, whereas a score of 3 indicates high severity or bother
of the symptom. The seven UTISA symptoms can be clustered into four symptom domains
(Clayson, et al., 2005). A schematic outline of the questionnaire is seen in Figure 1.
16S rRNA and Whole Genome Sequencing
To further characterize selected urinary isolates, genomic sequencing was used to
determine closely related strains, as well as to verify the taxonomic assignment by MALDITOF MS. To begin the process, pure bacterial cultures were taken from the isolate
collection (Brucella Broth vials stored at -80°C) and grown in their optimal environment
for 48 hours. Pure colonies were transferred to broth (Gardnerella – Tryptic Soy Broth
(TSB) supplemented with 10% Fetal Bovine Serum (FBS); Lactobacillus – de Man,
Rogosa, and Sharpe (MRS) broth) and grown in the same environment for 48 hours. To
isolate the genomic DNA, the urinary organism was centrifuged for 2 minutes at 13,000
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RPM, the supernatant liquid was decanted and the pellet was subjected to a phenolchloroform extraction protocol.
The genomic DNA was used for both Sanger Sequencing and Whole Genome
Sequencing (WGS).

The Sanger Sequencing method used the incorporation of

fluorescently tagged chain-terminating dideoxynucleotides by DNA polymerase during in
vitro DNA replication (Sanger et al., 1975, Smith et al., 1986). The bacterial genomic DNA
was used as a template to amplify the 16S rRNA gene using universal primers (11F and
1492R) and Polymerase Chain Reaction (PCR). The 1.5 kb gene was cloned into a pCR2.1TOPO plasmid (InvitrogenTM, Thermo Fisher Scientific Inc.) and introduced into Ca2+competent DH5α E. coli via transformation. The insertion of the PCR product into the
plasmid interrupted the lacZα gene. The full length LacZα subunit is required to form
functional β-galactosidase. The presence of active β-galactosidase was assayed by growing
the transformed E. coli on Luria-Bertani (LB) media with X-GAL (5-bromo-4-chloro-3indolyl-β-D-galactopyranoside) (Sigma-Aldrich, St. Louis, MO) (200µL of 20mg/mL XGAL into dimethylformamide (DMF)) . Formation of a blue-colored product, precipitated
within the cells causing the colonies to appear blue, was indicative of active βgalactosidase. Thus, white colonies were screened (indicative of a disrupted lacZα gene
and successful insertion of the bacterial PCR product). The pCR2.1-TOPO plasmid with
the 16S rRNA insert was purified using a QIAprep Spin Miniprep Kit (Qiagen, Valencia,
CA). The isolated plasmid was sent for Sanger Sequencing by GenScript (GenScript USA
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Inc., Piscataway, NJ). The resultant sequence was analyzed using the program LaserGene
(DNASTAR Inc., Madison, WI).
WGS was performed using the MiSeq Illumina desktop sequencer (Illumina, San
Diego, CA). Briefly, this method involved the random fragmentation of the full bacterial
genome, followed by ligation of oligonucleotides of known sequence onto either end of
each fragment. These fragments were amplified and then sequenced. The sequencing
involved the repetitive addition of four reversible terminator nucleotide bases, each of
which was fluorescently labeled. Once the non-incorporated nucleotides were washed
away, a camera imaged the incorporated fluorescent nucleotide. The nucleotides were then
chemically removed and the next cycle began. Raw sequences were processed using the
open-source program Mothur, v1.31.2 (Kozich et al., 2013). Paired ends were joined and
contigs of incorrect length (<285 bp or >300 bp) and/or contigs that contained ambiguous
bases were removed. Sequences were aligned using the SILVA database, and chimeric
sequences were removed with UCHIME (Edgar et al., 2011). These sequences, as well as
the full 16S rRNA gene sequences from the Sanger Sequencing, were compared to an
online database of known bacterial sequences (Basic Local Alignment Search Tool –
BLAST) (NCBI) to look for any homology greater than 97%, which is the typical threshold
for interspecies variability.
Urothelial Cell Invasion Assay
A non-malignant urothelial cell line (HURO23A) established by Dr. Phong Le (Le et al.,
2014) was used to assess the ability of urinary isolates to prevent the invasion of
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Uropathogenic E. coli (UPEC) into the urothelial cells. UPEC strain NU14 was plated onto
LB agar and incubated aerobically overnight at 37°C. A single colony of UPEC was
inoculated into 5mL of LB broth and incubated in the same conditions. Several subcultures
of UPEC were made into new LB media (1:1000) to ensure purity. The urinary isolates
(Lactobacillus crispatus) were grown in MRS broth and incubated in 5% CO2 at 37°C for
48 hours. The urothelial cells were counted with a hemocytometer and diluted to 105
cells/mL in tissue culture media (DMEM/F-12/5% FBS). 1 mL aliquots of urothelial cells
were placed into a 24 well plate in triplicate and incubated overnight in 5% CO2 at 37°C
to promote adherence of the cells.
The details of the invasion assay protocol are found in Figure 2. Two experimental
conditions were used. The first was a two-hour pretreatment of 107 CFU/mL of the urinary
isolates prior to addition of an equal concentration of UPEC. The other was a simultaneous
addition of equal concentrations of the urinary isolates and UPEC. The controls were the
addition of no bacteria and the addition of UPEC alone, which can invade the cells
normally. After addition of the bacteria, the 24 well plate was centrifuged at 1400 RMP for
5 minutes to initiate bacteria-urothelial cell contact. The plate was incubated in 5% CO2 at
37°C for 2 hours. The cells were then treated with 200 µg/mL Gentamicin for 2 hours to
remove extracellular bacteria. Next, the cells were washed with 1 mL PBS and then treated
with 1 mL 0.1% Triton-X-100 in PBS for 5 minutes. The lysed cells were serially diluted
and plated on LB agar to assess the average intracellular count per well of UPEC. This
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experimental setup was loosely based on a previously published protocol (Edelman et al.,
2003).
Competition Assays
Lawn Assay.
To assess the interactions between two microorganisms, a lawn assay was
performed. An overnight culture of UPEC (strain NU14) was grown in TSB aerobically at
37°C. This was diluted to an OD600 of 1.00. 1 mL of the culture was spun down at 13,000
RPM for 2 minutes, and the pellet was re-suspended in 100 µL to create a 10X concentrated
culture. 50 µL of the 10X UPEC culture was added to 700 µL fresh TSB and plated on
Tryptic Soy Agar (TSA). Once the lawn was completely dry, the second microorganism
was spotted. The urinary isolates (Lactobacillus) were grown for 48 hours in MRS broth
in 5% CO2 at 37°C. A 10X concentrated culture was made in the same manner as described
above. 5 µL of the 10X urinary isolate culture was added to the dry lawn of UPEC. The
plates were then incubated for 24 hours in 5% CO2. A variation of this protocol was 5 µL
of the un-concentrated supernatants of the urinary isolates (Figure 3).
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Figure 2. Protocol for the Urothelial Invasion Assay. The assay used the non-malignant
urothelial cell line, HURO23A and Uropathogenic E. coli (UPEC), strain NU14 and a
urinary isolate of Lactobacillus crispatus. Four different experimental conditions were
used: a positive control, UPEC alone condition; a negative control, no bacteria added
condition; a pre-treatment condition with L. crispatus (2 hours); and a co-inoculation
treatment (L. crispatus and E. coli added together). 100 µg/mL of Gentamicin was used to
wash off unbound bacteria, and 0.1% Triton-X 100 was used to lyse the urothelial cells to
assess internalized bacteria. Lysed cells were serially diluted and plated on LB plates and
incubated aerobically for 24 hours.
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Figure 3. Protocol for the Lawn Assay. UPEC was grown in Tryptic Soy Broth (TSB)
for 24 hours in aerobic-shaking conditions. The UPEC culture was diluted to an OD600 of
1.00. 1 mL of the UPEC culture was centrifuged (10,000 RPM for 4 min), the supernatant
was removed, and the pellet was resuspended in 100 µL of fresh TSB (10X concentrated
solution). 50 µL of the concentrated UPEC solution was added to a Tryptic Soy Agar
(TSA) plate with 700 µL fresh TSB and evenly spread on the plate. Once dry, 5 µL of a
10X concentrated solution of the urinary isolate (L. crispatus depicted) (10X concentration
was obtained through the same method as UPEC) was spotted on to the lawn. A variation
of this protocol was to use the supernatant of the urinary isolate culture. The plates were
incubated in 5% CO2 for 24 hours.
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Growth Inhibition Assay.
To assess the interactions between two microorganisms in liquid culture, a growth
inhibition assay was performed. An overnight culture of UPEC (strain NU14) was grown
in TSB aerobically at 37°C. Various spent culture supernatants (SCS) of urinary isolates
(Lactobacillus and Gardnerella) were filter sterilized using a Nucleopore filter with a pore
size of 0.2 μm. These supernatants were added in a 1:1 ratio to the overnight cultures of
UPEC and incubated aerobically at 37°C shaking. At 0, 2, and 24 hours, 1 mL of the
cultures were collected, serially diluted in PBS, and were plated on TSA to assess the
average CFU/mL of UPEC in response to the various supernatants. (Figure 4). This assay
was performed in triplicate using three different strains of the various urinary isolates.
Ethidium Bromide Assay
To assess the effects of the SCS on UPEC, an Ethidium Bromide (EtBr) assay was
performed. The concept behind this assay is that EtBr will bind to DNA and will fluoresce
under UV light. Thus, use of EtBr can be used to assess the integrity of the envelope
including the cytoplasmic membrane. If the SCS induces lysis or acts to form a pore in the
membrane of UPEC, then the EtBr would be able to bind the genomic DNA and this
binding can be detected via UV light. The SCS were added in a 1:1 ratio to an overnight
culture of UPEC and then EtBr was added to the tube at a final concentration of 100 µmol/L
for 5 minutes before washing twice with equivalent volume of PBS. As a positive control,
UPEC was heat-lysed at 100°C for an equivalent amount of time as the SCS experimental
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condition. As a negative control, the UPEC was exposed to the media control. (Figure 5).
This protocol was based on the one used in Turovskiy et al., 2009.
Statistical Analysis
Statistical analyses were performed using SAS software version 9.3 and SYSTAT software
version 13.1. Pearson Chi-Square tests were used to compare frequency data between
cohorts (Chapters III & IV). The Pearson Chi-Square test was used on unpaired large
sample size data sets to evaluate the likelihood that an observed difference arose from
random chance. Student’s t-tests for independent samples (two-tailed) were performed on
data from the competition assays (Chapter V). The Student’s t-test was used on normally
distributed data sets to determine if the sets are statistically different from one another.
Pearson’s Correlation Coefficient (Pearson’s r) was used to assess correlations between the
FUM and various urinary symptoms. This is a measure of the linear correlation between
two variables. The Shannon Diversity Index and Simpson’s Index were used to assess
differences in biodiversity (alpha-diversity) between microorganism communities
associated with different cohorts (Chapters III & IV). The Shannon Diversity Index is a
measure of uncertainty in selecting the next randomly chosen microorganism. A higher
Shannon Diversity score corresponds to more uncertainty, and thus higher biodiversity.
The effective number of species (ENS) was calculated by taking ex of the Shannon
Diversity scores. The ENS value refers to the number of species that are equally distributed
in the population. The Simpson’s Index is a measure of the chance that two randomly
selected microorganisms are the same species. These values can range from 0 to 1, where
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a value of 0 corresponds to no diversity (a population of all the same species) and a value
of 1 corresponds to infinite diversity.
Graphs were generated using Microsoft Excel 2013, PlotlyTM 2015, SAS 9.3, and
SYSTAT 13.1.
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Figure 4. Protocol for the Growth Inhibition Assay. UPEC was grown in Tryptic Soy
Broth (TSB) for 24 hours in aerobic-shaking conditions. The urinary isolates were grown
in MRS broth for 48 hours in 5% CO2 conditions. 2 mL of the UPEC culture were added
to 2mL of the filtered supernatants of the urinary isolates and incubated in aerobic-shaking
conditions for various timepoints. At each timepoint, serial dilutions were made and plated
on Tryptic Soy Agar (TSA) plates. The plates were incubated in aerobic conditions for 24
hours and then assessed for UPEC growth/viability.
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Figure 5. Protocol for the EtBr Susceptibility Assay. The figure depicts the protocol for
the Ethidium Bromide (EtBr) Assay. The assay assesses Uropathogenic E. coli (UPEC),
strain NU14 and a urinary isolate of Lactobacillus crispatus. An overnight culture of
UPEC was added in a 1:1 ratio with the filtered supernatant of L. crispatus. 100µL of EtBr
(final concentration of 100µmole/L) was added to assess the integrity of the UPEC
cytoplasmic membrane and visualized under UV light. As a positive control, UPEC was
added in a 1:1 ratio with Tryptic-Soy Broth (TSB) and heat-lysed at 100°C. As a negative
control, UPEC was added in a 1:1 ratio with the media control from L. crispatus, MRS
broth.

CHAPTER III
THE FUM OF WOMEN WITH
URINARY INCONTINENCE
Introduction & Rationale
Urinary incontinence refers to the involuntary leakage of urine.

Urgency urinary

incontinence (UUI) is a form of overactive bladder syndrome (OAB) that encompasses
both the feelings of urgency along with involuntary leakage (Stewart et al., 2003). It
represents one of two subcategories of urinary incontinence; the other being Stress Urinary
Incontinence (SUI), which is not a form of OAB, but rather involuntary leakage during
physical exertion, such as coughing, sneezing, laughing, or exercise. While it is common
for adult women affected by incontinence to have elements of both subtypes (mixed urinary
incontinence), typically one subtype predominates. The etiology of SUI is understood to
be a sphincteric deficiency, which likely occurs with age and can be treated effectively
with surgery (Cundiff, 2004). The etiology of UUI is related to that of OAB, which is
thought to be related to abnormalities in detrusor muscle regulation. One possible cause is
a neurological disorder due to increased release of the neurotransmitter acetylcholine,
which binds to the muscarinic receptor on the detrusor muscle surrounding the bladder,
causing contractions and the feelings of urgency (Michel et al., 2009). Therefore, treatment
of OAB, with or without incontinence (i.e., UUI), is often via administration of antimuscarinic drugs (Michel et al., 2009). However, current UUI therapy is suboptimal, a
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many affected patients have persistent symptoms despite treatment with medications
and/or other UUI therapies (Santos et al., 2010). This suggests that there exist etiologies
outside of neruo-muscular dysfunction. Recently, our group demonstrated a correlation
between the FUM and presentation of OAB symptoms with urinary incontinence (Pearce
et al., 2014). The FUM of UUI and non-LUTS women are distinct in species richness and
abundance, as well as composition (Pearce et al., 2014). Thus, it may be possible to direct
therapies towards the bladder microbiota, which could in turn affect the efficacy of UUI
treatment, or the symptoms themselves.
To understand the role of the FUM in LUTS, EQUC was used to assess the
microbiota composition of women with the various forms of urinary incontinence, with the
hypothesis that women with SUI, a physical abnormality affecting the urogenital tract,
should have a FUM that is different from UUI, which is characterized by specific urinary
symptoms. Thus, the FUM of women with SUI would be likely to be more similar to that
of continent women than to that of women with UUI. Additionally, the FUM of women
with urinary incontinence (regardless of subtype) is likely different from that of continent
women. The act of excessive involuntary loss of urine creates a distinct physical urogenital
environment that differs dramatically from women without urinary incontinence.
Urinary Incontinence Study
Overview of Study.
A prospective study with IRB approval was conducted between 2013 and 2015 in
which women presenting to the urogynecology clinic were grouped into three categories:
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UUI, SUI, and Continence. Participants' symptoms were characterized with the Pelvic
Floor Distress Inventory (PFDI), a self-completed, validated symptom questionnaire (Due
et al., 2013). Participants also completed the Pelvic Organ Prolapse Quantification (POPQ)
assessment, to quantify the degree of organ prolapse. TUC urine samples were collected
from all three patient groups.
Patient recruitment for this study will ultimately total 150 women. There will be 50
women recruited into the UUI cohort, 50 women recruited into the SUI cohort, and 50
women recruited into the Continence cohort. Exclusion criteria include: women who
cannot communicate or read in English, women under the age of 18, pregnant women, and
women with an indwelling catheter.
The TUC urine specimens were assessed for bacterial growth using the standard
urine culture protocol as well as the EQUC protocol (Table 1) (Hilt et al., 2014). The
standard urine cultures were performed by the Clinical Microbiology Laboratory staff at
Loyola University Medical Center. All patient care was a consequence of the results of the
standard culture alone; the EQUC results were been reported and thus did not impact
patient care. In December 2014, the Clinical Microbiology Laboratory began using the
modified urine culture protocol (Table 1). This change affected patients with the study
ID’s UUI50, SUI39-50, and C016-24 (patients 102-124).
Comparison of the FUM among Incontinence Subtypes.
At the time of writing (May 2015), recruitment for this study has not been
completed. All data, calculations, and conclusions for this study are based on the
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recruitment of the first 124 participants. These include all 50 women in the UUI cohort, all
50 women in the SUI cohort, and 24 women in the Continence cohort. This may create a
bias in the data since the three cohorts are not equal.
Of the 124 TUC urine samples, 97 (78.2%) had bacterial growth. The median
number of unique bacterial species per urine sample was one (IQR=1-4) for the UUI cohort,
three (IQR=1-4) for the SUI cohort, and two (IQR=0-3.5) for the Continence cohort [(UUI
& SUI [p=0.256], UUI & Continence [p=0.984], SUI & Continence [p=0.353]). The
interquartile range (IQR) is a measure of data dispersion. Thus, in general, the women in
the SUI cohort had a more diverse urinary microbiota than those in the UUI cohort. These
data are summarized in Table 2.
Amongst the 124 urine samples, 77 different species of microorganisms were
identified using MALDI-TOF MS. These species came from 5 different phyla
(Actinobacteria, Firmicutes, Proteobacteria, Ascomycota, and Bacteroidetes) and 31
different genera.
The overall false negative rate for standard/modified urine culture was 85.71%. 83
of the 97 urine samples that had bacterial growth were deemed “no growth” using the
routine cultures.
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Table 2. Overview of Urine Cultivation for Incontinence Study. The table lists various
descriptive values for each cohort. The TOTAL column lists values for all 124 samples
combined.
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In terms of diversity, as previously mentioned, the SUI cohort appeared to have a
more diverse FUM than the UUI cohort, with the continence cohort falling in between.
However, when this is depicted graphically (Figure 6A), in terms of a rarefaction curve,
there did not appear to be a difference between the UUI and SUI cohorts in terms of
diversity. Rarefaction is a technique used to assess species richness for a group of
individual samples. The curve plots the number of unique species as a function of the
number of samples (patients recruited). As the curve plateaus, this corresponds to the
saturation of the given population. A difference in diversity would be represented by two
curves with different plateaus or trajectories.
The UUI cohort contained 57 unique species, the SUI cohort contained 53 unique
species, and the Continence cohort contained 28 unique species. The curves for UUI and
SUI appeared very similar, while the curve for the Continence cohort may be plateauing at
a lower number of unique species, but it is not yet clear from the existing data. Statistical
analyses of these data support these claims. The Shannon Diversity Index for the UUI
cohort was 3.686, for the SUI cohort it was 3.670, and for the Continence cohort it was
3.126. The effective number of species for the UUI cohort was 40, for the SUI cohort it
was 39, and for the Continence cohort it was 23. Together, these data show that the
Continence cohort was comprised of a statistically less diverse FUM than either
Incontinence cohort. The UUI and SUI cohorts appeared very similar in terms of FUM
diversity.
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Figure 6. Rarefaction Analysis of Incontinence & Continence Cohorts. (A) The SUI
cohort (N=50) contains 53 unique species and is depicted by the blue circles. The UUI
cohort (N=50) contains 57 unique species and is depicted by the red squares. The
Continence cohort (N=24) contains 28 unique species and is depicted by the green
diamonds. (B) The Incontinence cohort (N=100) contains 75 unique species and is depicted
by the blue circles. The Continence cohort (N=75) contains 48 unique species and is
depicted by the red squares. The Continence cohort combines the Continence cohort from
this study (N=24) and from Pearce et al., 2014 (N=51).
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Figure 7. Microbiota Profiles of Incontinence & Continence Cohorts. Depicts the
genus-level microbiota composition based on percent CFU/mL urine for the given patient
urine sample. The UUI cohort (top) contains 50 urine samples, the SUI cohort (middle)
contains 50 urine samples, and the Continence cohort (bottom) contains 24 urine samples.
The figures have been stretched to be equivalent sizes for better qualitative comparisons.

39

Figure 8. Frequency of Genera in Incontinence & Continence Cohort. (A) The SUI
cohort (N=50) is depicted by the blue bars, the UUI cohort (N=50) is depicted by the red
bars, and the Continence Cohort (N=24) is depicted by the green bars. (B) The Incontinence
cohort (N=100) is depicted by the blue bars, and the Continence cohort (N=75) is depicted
by the red bars. Denoted are the genera that are statistically associated with either cohort,
as determined by a Pearson Chi-square test for significance (* p<0.05; ** p<0.01)
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When assessing the composition of the FUM among the cohorts, there were several
noticeable differences. The microbiota profiles for the three cohorts are seen in Figure 7.
These are graphical representations of the genus-level composition based on the CFU/mL
obtained for each genus. There were more culture negative samples in the Continence
cohort than either Incontinence group. The SUI cohort had the least relative amount of
culture negative samples. The number of diverse samples (more than one or two dominant
genera) was also greater in both Incontinence groups than the Continence cohort. There
were more Corynebacterium-dominant samples in the UUI cohort than either the SUI or
Continence cohorts. There were also no Staphylococcus-dominant samples in the
Continence cohort. Finally, Bacillus and Micrococcus-dominant samples were only found
in the Continence cohort.
In terms of frequency of detection among the urine samples of the three cohorts,
there were also several trends (Figure 8A). At the genus level, there were higher levels of
Micrococcus, Lactobacillus, and Gardnerella in the Continence cohort, whereas there were
higher levels of Actinobaculum, Staphylococcus, Streptococcus, and Rothia in the SUI
cohort. Rothia was noticeably absent from the Continence cohort. At the species level,
Corynebacterium minutissimum, Lactobacillus crispatus, Lactobacillus gasseri, and
Micrococcus luteus were all associated with the Continence cohort. Corynebacterium
aurimucosum, Actinobaculum schaalii, Rothia dentocariosa, and Rothia mucilaginosa
were all associated with the SUI cohort. Finally, Actinomyces turicensis was associated
with the UUI cohort (Figure S2).
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Together, these data show that the FUM is moderately distinct between all three
cohorts, which suggests that certain bacterial communities correspond to specific lower
urinary tract disorders or lack thereof. However, contrary to one of the initial hypotheses,
the SUI cohort did not appear similar to the Continence cohort. If anything, SUI looked
more like UUI, especially in terms of diversity. This suggests that the FUM is distinct
between urinary incontinence and continence.
Comparison of the FUM between Incontinence and Continence.
By combining the UUI and SUI cohorts into a larger “Incontinence” cohort, there
appeared to be larger distinctions from the Continence cohort; more so than either
incontinence subgroup individually. The Incontinence cohort was comprised of 100
patients, while the Continence cohort only contained 24. To reduce bias, we balanced these
numbers by adding the Continence cohort from Pearce et al. (2014) to these 24 patients.
The 51 continent patients from Pearce et al. (2014) were recruited, sampled, and assessed
in an identical manner as the patients from this study. The diversity between the continence
groups was comparable. The Shannon Diversity Indices were 3.126 (Present Study) and
2.998 (Pearce et al., 2014). Figure 9 shows that the microbiota profiles for the two groups
were also vastly similar. The relative amounts of Lactobacillus, Gardnerella,
Streptococcus, and Escherichia dominant samples, as well as the amounts of culture
negative samples, were nearly identical, although there were slight differences in the more
diverse samples. For example, the Continence cohort in Pearce et al. (2014) contained
Enterococcus, Candida, Alloscardovia, and Micrococcus-dominant samples, while the
Continence cohort in this study contained Bacillus and Micrococcus-dominant samples.
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Generally, the two groups were very comparable and were thus combined into a larger
Continence cohort (N=75).
When comparing the Incontinence cohort (N=100) with the Continence cohort
(N=75), we observed large differences in diversity. The median number of unique species
per urine sample for the Incontinence cohort was two (IQR=1-4), while the median for the
Continence cohort was one (IQR=0-2) [p=0.012]. These differences are also seen in Figure
6B, which depicts the data as rarefaction curves. The Incontinence cohort contained 75
unique species, whereas the Continence cohort contained 48 unique species. The curve for
the Continence cohort plateaued at a much lower number of unique species than the
Incontinence curve. Statistical analyses of these data supported these claims. The Shannon
Diversity Index for the microorganism communities of the Incontinence cohort was 3.833,
and for the Continence cohort 3.149. The ENS for the Incontinence cohort was 46 and for
the Continence cohort it was 23.
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Figure 9. Microbiota Profiles of Continent Controls. The figure depicts the genus-level
microbiota composition based on percent CFU/mL urine for the given patient urine sample.
The Continence cohort from Pearce et al., 2014 (top) contains 51 urine samples and the
Continence cohort from the current study (bottom) contains 24 urine samples. The figures
have been stretched to be equivalent sizes for better qualitative comparisons.
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Figure 10. Frequency of Significant Species between Incontinence & Continence
Cohorts. The Incontinence cohort (N=100) is depicted by the blue bars, and the Continence
cohort (N=75) is depicted by the red bars. Depicted are the species that are statistically
associated with either cohort. The degree of association is denoted. The values are
determined by a Pearson Chi-square test for significance (* p<0.05; ** p<0.01).
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At the genus level, in terms of microbiota profiles, the Continence and Incontinence
cohorts looked quite different (Figure S3). About one-third of the samples in the
Continence cohort were EQUC-negative, while only about 10% of the samples in the
Incontinence cohort were negative. Additionally, the profiles highlighted the large
differences in diversity. Generally, samples in the Incontinence cohort contained three to
four dominant genera, while the Continence cohort was dominated by just one or two.
There were also fewer Gardnerella-dominant samples in the Continence cohort, and no
Corynebacterium-dominant samples. Interestingly, there were about equivalent numbers
of Lactobacillus, Streptococcus, and Staphylococcus-dominant samples between the two
cohorts. In terms of frequency of association, four genera were statistically associated with
either cohort. The three genera that were associated with the Incontinence cohort were:
Aerococcus [p=0.01], Corynebacterium [p=0.02], and Actinobaculum [p=0.05] (Figure
8B). The one genus that was associated with the Continence cohort was Micrococcus
[p=0.04]. At the species level, six microorganisms were statistically associated with either
cohort. The five microorganisms associated with the Incontinence cohort were:
Actinobaculum schaalii [p=0.05], Actinomyces turicensis [p=0.05], Aerococcus
sanguinicola [p=0.05], Aerococcus urinae [p=0.02], and Corynebacterium lipophile group
[p=0.02] (Figure 10). MALDI-TOF MS cannot distinguish between the various species of
Corynebacterium that full under the category “lipophile group”. The one microorganism
associated with the Continence cohort was Micrococcus luteus [p=0.04] (Figure 10). A
chart of the frequencies of all the species between the cohorts is depicted in Figure S5. A.
schaalii, A. urinae, and A. sanguinicola are emerging uropathogens that are commonly
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associated with infection, but have not been studied extensively (Bank et al., 2010,
Senneby et al., 2014). A. turicensis is commonly found on mucosal membranes and has
been associated with vaginal and urinary infections (Chudackova et al., 2010). Thus, it is
very intriguing that many of the microorganisms associated with the incontinence group
have pathogenic capabilities. Therefore, the hypothesis that these bacteria contribute to
incontinence is not far-fetched. M. luteus, the one microorganism that is associated with
the Continence cohort, may have probiotic characteristics. Metabolites produced by
environmental isolates of M. luteus have been found to be inhibitory towards a wide range
of pathogens, including several known uropathogens (Akbar et al., 2014).
Overall, it seems that the FUM of women with incontinence is significantly
different from continent women. The implication of this are that the microbiota may have
a role in etiologies of incontinence. However, considering that there is not a dramatic
difference in the FUM (in terms of diversity and composition) between the different
subgroups of urinary incontinence (UUI & SUI), it may in fact be that the FUM is more of
a result of the physical environment of the urogenital tract. Women with urinary
incontinence are continually leaking urine, creating a wet environment that may be more
suitable to the growth and colonization of a distinct group of microorganisms compared to
those associated with healthy women. Whether these communities of microorganisms
could then act in turn to exacerbate the urinary symptoms.

CHAPTER IV
ASSESSING THE RELATIONSHIP BETWEEN
THE FUM AND URINARY SYMPTOMS
Introduction & Rationale
With the knowledge that the FUM is significantly distinct between incontinent and
continent women (this study), as well as between women with UUI and continent women
(Pearce et al., 2014), it is reasonable to hypothesize that these microorganisms, as a single
entity, or as a complex community, can contribute to these etiologies. However, the
findings that the FUM of women with UUI or SUI are rather indistinguishable (Chapter
III) could suggest the opposite; that the FUM are more a result of the physical environment:
dry or moist. Thus, these data would suggest that the FUM does not cause the various
disorders, but rather is a consequence of them. Since both theories are entirely plausible,
the FUM of one more group of women was assessed: women with and without UTIs. UTIs
can manifest themselves through a variety of symptoms, and are known to be a direct result
of the presence of microorganisms. Thus, this group of women present an ideal opportunity
to test if the FUM has any correlation with specific urinary symptoms outside of current
definitions for urinary infection, as opposed to simply being a consequence of a urinary
disorder.
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Urinary Tract Infections
Most uncomplicated UTIs occur in women (Wien, 2007). At least 50% of women will have
at least one infection during their lifetime, making UTIs a significant public health concern
(Wien, 2007). Furthermore, UTIs are the most common nosocomial infections, annually
costing $1.6 billion in the United States alone (Foxman, 2002). Typically, patients with an
uncomplicated UTI present with symptoms that can include, but are not limited to, one or
more of the following: urinary frequency and urgency, painful urination (dysuria), lower
pelvic pain and/or lower back pain, new or increased urinary incontinence, malodorous
urine, and blood in the urine (hematuria) (Wien, 2007, Clayson et al., 2005). These
symptoms, in addition to a positive standard urine culture of ≥105 CFU/mL of known
uropathogens, usually leads clinicians to treat the patient with an appropriate antibiotic
regimen. Notably, some patients are given antibiotics prior to culture results based on their
symptoms alone.
UTI Study
Overview of Study.
A prospective study with IRB approval was conducted between 2014 and 2015, in
which women presenting to the urogynecology clinic were asked if they felt they had UTI
symptoms and were separated into two groups based on their responses: “YES” and “NO”.
Both patient populations completed a brief demographics questionnaire, as well as the
validated UTISA questionnaire (Clayson et al., 2005), to assess the degree of severity and
bother of various common UTI symptoms. TUC urine samples were collected from both
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groups. Additionally, the YES cohort was asked to complete a follow-up UTISA
questionnaire by phone, 1 to 2 weeks after the initial visit, as an assessment of whether
their clinical treatment resolved, or did not resolve, their symptoms. A schematic outline
of the study design is depicted in Figure 11.
Patient recruitment for this study will be a total of 150 women. There will be 75
women recruited into the YES cohort and 75 women recruited into the NO cohort.
Exclusion criteria include: women who cannot communicate or read in English, women
under the age of 18, pregnant women, and women with an indwelling catheter.
The TUC urine specimens that are collected from all 150 women will be assessed
for bacterial growth using the standard urine culture protocol as well as the expanded
EQUC protocol (Table 1). The expanded EQUC protocol adds MacConkey agar and
Campy gas mixture to the original EQUC protocol (Hilt et al., 2014). MacConkey agar is
ideal for the growth of typical uropathogens, and the Campy gas mixture provides an
optimal environment for the isolation of fecal contaminant microorganisms.
The standard urine culture was performed by the Clinical Microbiology Laboratory
staff at Loyola University Medical Center. All patient care was a consequence of the results
of the standard culture alone; the expanded EQUC results have not been reported and thus
have not impacted patient care. In December 2014, the Clinical Microbiology Laboratory
began using the modified urine culture protocol (Table 1). This change has affected
patients with study IDs 108-118.
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Figure 11. Flow Chart for the UTI Study. Schematic outline of the study design.

51

This study serves an additional purpose, which is documented in Appendix A. The
use of three volumes of urine for the expanded EQUC is intended to determine an optimal
urine culture protocol for recommendation to the clinical microbiology community as a
better method for detecting clinically relevant microorganisms (uropathogens). Thus, for
this study, the data obtained from all three urine volumes of the expanded EQUC protocol
were combined. Additionally, all reported data were taken strictly from the 48 hour
timepoint.
After 48 hours of incubation in the respective environmental conditions, the various
plates were documented for morphologies and sub-cultured. The pure cultures were
identified using MALDI-TOF MS, and were stored at -80°C for future study.
Comparison of the YES and NO Cohorts.
At the time of writing (May 2015), recruitment for this study has not completed.
Thus, all data, calculations, and conclusions for this study are based on the recruitment of
the first 118 women. This recruitment includes all 75 women in the NO cohort and 43
women in the YES cohort. This may create a bias in the data since the two cohorts are not
equal.
Of the 118 TUC urine samples, 108 (91.5%) contained viable bacteria. The median
number of unique bacterial species per urine sample was two (IQR=1-3) for the YES
cohort, and three (IQR=1-5) for the NO cohort [p=0.067]; thus, on average, the women in
the YES cohort had a less diverse urinary microbiota than those in the NO cohort. These
data are summarized in Table 3.
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Table 3. Overview of Urine Cultivation for the UTI Study. The table lists various
descriptive values for each cohort. The TOTAL column lists values for all 118 samples
combined.
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Amongst the 118 urine samples, 84 different species of microorganisms were
identified using MALDI-TOF MS. These species represent 4 different phyla
(Actinobacteria, Firmicutes, Proteobacteria, and Ascomycota) and 31 different genera.
The overall false-negative rate for standard/modified urine culture was 70.37%. 76
of the 108 urine samples that had bacterial growth were deemed “no growth” by the
standard culture protocol. For the YES cohort alone, the false-negative rate was 35.00%;
for the NO cohort, it was 92.65%.
The diversity, genus level microbiota composition, and species level composition
differ greatly between the YES and NO cohorts. As previously mentioned, the YES cohort
appeared to have a less diverse FUM than the NO cohort. This is depicted graphically in
Figure 12 in the form of a rarefaction curve. This analysis assesses the species richness for
a group of individual samples, and the data are plotted as the number of unique species as
a function of the number of patients recruited. The plateau of the curve corresponds to the
saturation of the given population. A difference in diversity would be represented by two
curves with different plateaus. This appears to occur for these data. The NO cohort
contained a bacterial population of 75 unique species and the YES cohort contained 42
unique species. The YES cohort appeared to plateau at a lower number of unique species
than the NO cohort, inferring less diversity. Statistical analyses of these data support the
claim of different diversities. The Shannon Diversity Index for the YES cohort was 3.339
and for the NO cohort it was 3.892. The ENS for the YES cohort was 28, and for the NO
cohort it was 49. Thus, the bacterial population of the NO cohort was comprised of a more
diverse FUM than the YES cohort and this difference was statistically significant.
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Figure 12. Rarefaction Analysis of YES & NO cohorts. The YES cohort (N=43)
contains 42 unique species and is depicted by the blue circles. The NO cohort (N=75)
contains 75 unique species and is depicted by the red squares.
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In addition to diversity, the YES and NO cohorts also differed in their
microorganism composition. The microbiota profiles for the two groups are seen in Figure
13. These are graphical representations of the genus-level composition based off of the
CFU/mL of each genus. The NO cohort contained more Lactobacillus, Corynebacterium,
and Streptococcus-dominant samples, while the YES cohort contained more Escherichia
and Klebsiella-dominant samples, and notably no Gardnerella-dominant samples. The NO
cohort, however, contained more EQUC-negative dominant samples. Additionally, the
microbiota profiles highlight the difference in overall diversity between the two cohorts.
On average, samples in the NO cohort contained 3 to 4 dominant genera per urine sample,
while samples in the YES cohort only contained 1 to 2.
In terms of frequency of detection among urine samples, Streptococcus [p=0.038]
and Gardnerella [p=0.047] were statistically associated with the NO cohort, while
Escherichia [p<0.001] was strongly statistically associated with the YES cohort. These
frequencies are depicted in Figure 14. Other trends, though non-statistically significant,
included: Actinobaculum [p=0.084], Corynebacterium [p=0.103], and Actinomyces
[p=0.128] associated with the NO cohort, and Klebsiella [p=0.113] associated with the
YES cohort. These frequencies represent similar conclusions made by assessment of the
microbiota profiles in Figure 13.
Four species were statistically associated with either cohort. The three species that
were associated with the NO cohort were: Gardnerella vaginalis [p=0.047], Streptococcus
parasanguinis [p=0.027], and Streptococcus mitis/oralis/pneumoniae [p=0.041]. MALDITOF MS cannot distinguish between the species S. mitis, S. oralis, and S. pneumoniae
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confidently, and were thus grouped together for these analyses. The one species associated
with the YES cohort was Escherichia coli [p<0.001]. These values are depicted in Figure
15. A chart of the frequencies of all the species between the cohorts is depicted in Figure
S7. It is not surprising that Escherichia coli was strongly associated with the YES cohort
as it is the most common cause of UTIs (Nicolle, 2008). Streptococcus parasanguinis is
associated with healthy microflora in the oral cavity (Corby et al., 2005). Streptococcus
pneumoniae is the causative agent of Pneumococcal Infection, which is responsible for a
large percentage of community-acquired pneumonia as well as bacteremia and bacterial
meningitis (Verma et al., 2012). Again, whether the isolates found in these urine sample
are S. pneumoniae is unclear. Streptococcus mitis and oralis are commonly found in the
oral cavity and have a slight association with endocarditis (Lamas et al., 2003, Marsh et al,
1999). It is interesting that Gardnerella vaginalis was associated with the NO cohort, as it
is a known biomarker for Bacterial Vaginosis (BV), a dysbiosis of the vaginal tract
(Eschenback, 2007). This findings reinforce that the women in the NO cohort are not
entirely devoid of lower urinary tract symptoms. It is possible that the role of G. vaginalis
in the bladder may be distinct from its role in the vagina. For example, G. vaginalis was
found to be statistically associated with women with UUI (Pearce et al., 2014), and many
of the women in the NO cohort have incontinence.
Taken together, these data further support the claims made in Chapter III that the
FUM is distinct between various LUTS. It seems that the FUM is not only distinct in terms
of diversity and composition between women with and without incontinence, but also
between women who do and do not feel they have a UTI based upon their symptoms.
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Figure 13. Microbiota Profiles of YES & NO Cohorts. Depicts the genus level
microbiota composition based on percent CFU/mL urine for the given patient urine sample.
The NO cohort (top) contains 75 urine samples and the YES cohort (bottom) contains 43
urine samples. The figures have been stretched to be equivalent sizes for better qualitative
comparisons.

58

Figure 14. Frequency of Genera in YES & NO Cohorts. The YES cohort (N=43) is
depicted by the blue bars, and the NO cohort (N=75) is depicted by the red bars. Denoted
are the genera that are statistically associated with either cohort, as determined by a
Pearson Chi-square test for significance (* p<0.05; ** p<0.01).
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Figure 15. Frequency of Significant Species between YES & NO Cohorts. The YES
cohort (N=43) is depicted by the blue bars, and the NO cohort (N=75) is depicted by the
red bars. Depicted are the species that are statistically associated with either cohort. The
degree of association is denoted. The values are determined by a Pearson Chi-square test
for significance (* p<0.05; ** p<0.01).
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FUM and Symptom Correlations.
The validated UTISA questionnaire is a self-administered questionnaire that asks
the patient to rate the degree of severity and bothersome on a scale of 0 to 3, for seven
classic UTI symptoms. These seven symptoms can be grouped into four broader symptom
domains termed urination regularity, problems with urination, pain associated with UTI,
and blood in the urine. The average domain scores can range from 0 to 12, except Blood in
the Urine, which can range from 0 to 6. These groupings are detailed in Figure 1.
To make appropriate correlations between the UTISA symptoms and the FUM, we
must first verify that the NO cohort is acting as an appropriate negative control. We would
expect that the women in the YES cohort give higher scores on the UTISA questionnaire
than the NO cohort, which is indeed the case (Figure 16). The average scores for urination
regularity were: YES cohort – 8.07 and NO cohort – 5.35 [p=0.0008]. The averages for
problems with urination were: YES cohort – 5.37 and NO cohort – 1.99 [p<0.00001]. The
averages for pain associated with UTI were: YES cohort – 4.28 and NO cohort – 2.13
[p=0.0012]. The average scores for blood in the urine were: YES cohort – 0.35 and NO
cohort – 0.11 [p=0.088]. The UTISA scores for three of the four domains were statistically
significant (p<0.05) using a two-tailed t-test for independent samples. These scores were
then compared to the average scores from the original UTISA validation study (Clayson et
al., 2005) (Figure 16). This study validated the UTISA questionnaire on 267 women, all
of whom had a UTI at greater than 103 CFU/mL of a uropathogen(s) (Clayson et al., 2005).
If the current study is similarly valid, then the scores for the YES cohort should be much
similar to the scores of Clayson et al., 2005, while the scores for the NO cohort should be
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much different. Figure 16 shows that this is the case. Therefore, the NO cohort acts as an
appropriate control for this study.
To assess whether there are correlations between the FUM and individual urinary
symptoms, the data were analyzed for differences in diversity, genus-level composition,
species-level composition, and community structure. Figure 17 is an assessment of the
difference in diversity of the urinary microbiota among the seven urinary symptoms. A
patient is included in the symptom grouping if she gave a non-zero severity or bother score
for that symptom. The Frequency of Urination cohort (N=90) contains 78 unique species,
the Urgency of Urination cohort (N=89) contains 75 unique species, the Pain or Burning
During Urination cohort (N=37) contains 52 unique species, the Urinary Retention cohort
(N=61) contains 68 unique species, the Pressure in Lower Abdomen cohort (N=52)
contains 64 unique species, the Low Back Pain cohort (N=40) contains 50 unique species,
and the Blood in Urine cohort (N=10) contains 20 unique species. There appear to be no
differences in diversity between any of the seven symptoms, as their trajectories appear
similar in Figure 17.
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Figure 16. Average UTISA Scores for YES & NO Cohorts. The average scores for the
four symptom domains for the YES (red bars) and NO (blue bars) cohorts, compared to
those from the UTISA Validation Study (Clayson et al., 2005) (green bars). Scores for
Urination Regularity, Problems with Urination, and Pain Associated with UTI range from
0-12. Scores for Blood in the Urine range from 0-6.
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Figure 17. Rarefaction Analysis of UTISA Symptoms. The Frequency of Urination
cohort (N=90) contains 78 unique species and is depicted by the blue circles. The Urgency
of Urination cohort (N=89) contains 75 unique species and is depicted by the red squares.
The Pain or Burning during Urination cohort (N=37) contains 52 unique species and is
depicted by the green diamonds. The Urinary Retention cohort (N=61) contains 68 unique
species and is depicted by the purple triangles. The Pelvic Pressure cohort (N=52) contains
64 unique species and is depicted by the blue x’s. The Low Back Pain cohort (N=40)
contains 50 unique species and is depicted by the orange pluses. The Blood in Urine cohort
(N=10) contains 20 unique species and is depicted by the dark blue dashes.
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Statistical analyses of these data support the claim of no difference in diversity.
The Shannon Diversity Index for Frequency was 3.858, Urgency was 3.833, Pain and
Burning was 3.678, Urinary Retention was 3.855, Pelvic Pressure was 3.847, Low Back
Pain was 3.567, and Blood in Urine was 2.932. Thus, there appear to be no large differences
in the diversity in the FUM of women presenting with each symptom. However, there are
some limitations to this conclusion. First, the degree of severity and bother are not
considered here, and neither is the CFU/mL of each cultured microorganism. The CFU/mL
could play a large role in symptoms. This is discussed more in Appendix A, although the
average total CFU/mL for urine samples included in each of the seven symptoms does not
differ dramatically among the symptoms. Also, most women present with multiple
symptoms at once; therefore, the values for diversity may be skewed as significant overlaps
exist.
In terms of the composition of the urinary microbiota among the seven urinary
symptoms, there did not appear to be any large differences in the genus-level composition
of each symptom (Figure 18). These data are presented in terms of average relative
abundance, which was calculated by averaging the percent CFU/mL for each genera across
the seven symptom groups. These data are essentially a summary of the microbiota profiles.
While no large differences were noticeable, there were some subtle differences between
symptoms. For example, there were more Escherichia and Klebsiella in the Pain and
Burning symptom group relative to the other six symptoms. There were also fewer
Lactobacillus and Gardnerella. There were fewer Staphylococcus and more
Corynebacterium in the Pelvic Pressure symptom group relative to the other symptoms.
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Frequency, Urgency, and Urinary Retention looked similar in their average relative
abundances of all the genera, while Blood in the Urine and Low Back Pain looked much
different from the other symptoms. Overall, there were minor differences in the average
relative abundances of the various genera among the seven symptoms, but no major
distinctions.
At the species level, however, there were noticeable differences among the seven
urinary symptoms. Figure 19 shows that all seven symptoms had a unique microorganism
profile associated with them. These data are presented in the form of a heat map with
associations displayed as “degree of association”. Thus, Figure 19 assesses how likely it
is for a given microorganism to be cultured from the urine of someone with the
corresponding urinary symptom. These data again do not take into consideration the degree
of severity or bother. An “association” is interpreted to be any non-zero score for either
severity or bother. In Figure 19, a degree of association of 1 (dark blue) is interpreted to
mean that the microorganism is always cultured from the urine of someone with the
corresponding symptom. A degree of association of 0 (pale yellow) infers the opposite.
Both axes of the heat map are clustered using the appropriate Dendogram, which is formed
using Euclidean distance.

66

Figure 18. Average Relative Abundances of Genera for UTISA Symptoms. Average
relative abundances are calculated by averaging the percent CFU/mL of each genera
found in all patients included in that symptom group and dividing by 100. Frequency
cohort (N=90), Urgency cohort (N=89), Pain & Burning cohort (N=37), Urinary
Retention cohort (N=61), Pelvic Pressure (N=52), Blood in Urine (N=10).
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From these data (Figure 19), three distinct populations appear. On the bottom
section of the heat map are the microorganisms that are strongly associated with several
symptoms. Many of these microorganisms include known uropathogens (e.g. Citrobacter
koseri, Pseudomonas aeruginosa, Candida albicans), but other organisms are also
included (e.g., Bifidobacterium breve). In the middle section of the heat map are the
microorganisms that are moderately associated with several of the symptoms. These
organisms (including Escherichia coli, Gardnerella vaginalis and several species of
Lactobacillus) may be interpreted to be biomarkers for those symptoms, part of the normal
flora, or actual causes of the symptoms. The role of these organisms is currently unclear.
The top section of the heat map are the microorganisms that are strongly associated with a
few symptoms. Many of these microorganisms are also known uropathogens, but several
of them have also only been cultured once or twice. Therefore, for these organisms, the
values for the degree of association may be skewed.
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Figure 19. Clustered Heat Map of Associations between Urinary Microbiota and
UTISA Symptoms. Associations are displayed as “degree of association” - how likely is
it for a given organism to be cultured from the urine of someone with the corresponding
urinary symptom (regardless of score). Both axes are clustered using the corresponding
Dendogram, which is measured in terms of Euclidean distance.

To help address some of the issues raised by Figure 19, Figure 20 presents the
same data in terms of correlation, also in the form of a heat map. A Pearson’s r Correlation
value was calculated for each microorganism-symptom pairing, and then clustered using a
Dendogram based off of Euclidean distance. These correlation values assess the linear
correlation between presence of a particular urinary symptom and presence of the
corresponding microorganism. The values can range from -1 to 1, where negative values
denote negative correlations, and positive values denote positive correlations. For this data
set, correlation values greater than 0.181 or less than -0.181 are statistically significant
(p<0.05). This figure is asking a slightly different question than Figure 19. In Figure 19,
the associations were based off of the likelihood of someone with a particular
microorganism in their urine sample having the corresponding symptom. Whereas Figure
20 asks what is the likelihood (in terms of correlation) of someone with a particular
symptom having the corresponding microorganism in their urine sample. Thus, the two
figures are comparable as a whole, but individual values are not. The clustering of Figure
20 also resulted in several distinct groupings. There are several organisms that appeared
red or blue across all of the seven symptoms. These microorganisms were either positively
(blue) or negatively (red) associated with the urinary symptoms as a whole; those that were
positively associated with symptoms (red) could have a protective effect on urinary health,
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whereas those negatively associated (blue) could cause symptoms or promote the
colonization of microorganisms that cause symptoms. Several microorganisms appeared
grey across the seven urinary symptoms. These microorganisms could be part of the normal
flora of the bladder, but do not significantly influence symptoms. They are likely involved
in maintaining a degree of homeostasis. Interestingly, not all of the uropathogens appeared
entirely blue across the seven symptoms. Some, like E. coli, tended to have strong positive
correlations with selected symptoms, while others (e.g. Streptococcus anginosus) actually
appear to be negatively correlated with all symptoms.
A factor that may be impacting these results is the CFU/mL with which the
microorganisms were cultured. For example, Enterococcus faecalis (a Gram-positive
uropathogen) appeared to exhibit strong distinctions in the degree of associations with the
various UTISA symptoms when the data is broken up in terms of CFU/mL (Figure 21). If
the CFU data is broken up into four groups (10, 11-99, 100-999, and ≥1000), there is a
trend that the higher the CFU/mL of E. faecalis, the greater the degree of association is
with several of the symptoms. Thus, the data from Figures 19 & 20 may be strongly
impacted by considering the CFU data. However, this assumption is based solely upon the
data for one of the 84 different microorganisms that have been cultured from this patient
population.
A final way to assess the correlations between the FUM and the urinary symptoms
is to mathematically analyze the variances among the symptoms. Figure 22 is a principle
component analysis (PCA) of the UTISA symptoms in terms of their degree of association
with the FUM. These PCA plots are calculated by maximizing the potential variance
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among the variables and then plotting these values. The various components represent the
total possible variance for the group of variables. The first component, PC1, calculates the
highest possible variance, while the second component, PC2, calculates the next highest
possible variance, and so on. In Figure 22A, PC1 is plotted against PC2. PC1 accounted
for 35.45% of possible variance, and PC2 accounted for 17.45% of possible variance, for
a total of 51.80%. This plot allowed for mild separation of the data. In contrast, Figure
22B, which depicts PC2 plotted against PC3 (16.25%) for a total of 32.70% possible
variance, showed a much larger separation of the data. This analysis shows that the urinary
symptoms are distinct in their associations with the FUM, but the degree to which they are
distinct can vary greatly. Figure 22C plots PC1, PC2, and PC3 for a three dimensional
look at the variables. This plot accounted for 68.05% of the possible variance.
Collectively, these data are strongly suggestive that the species-level FUM is
directly involved in these individual symptoms and thus may be involved in the etiologies
of various lower urinary tract disorders that are defined by the particular symptoms.
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Figure 20. Clustered Heat Map of Correlations between Urinary Microbiota and
UTISA Symptoms. Correlations are calculated using Pearson’s R. Values are scaled
from scores of 0.5 to -0.5. Both axes are clustered using the corresponding Dendogram
which is measured in terms of Euclidean distance. Values greater than 0.181 or less than 0.181 are significant (p<0.05).

Figure 21. Heat Map of Associations between Enterococcus faecalis and UTISA
Symptoms Grouped by CFU. Associations are displayed as “degree of association” how likely is it for the organism to be cultured from the urine of someone with the
corresponding urinary symptom (regardless of score). E. faecalis has been cultured a
total of 12 times at CFU’s ranging from 10 to 100,000 CFU/mL. The 10 CFU/mL group
contains 4 samples, the 11-99 CFU/mL group contains 3 samples, the 100-999 CFU/mL
group contains 2 samples, and the ≥1000 CFU/mL group contains 3 samples.
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C.
Figure 22. Principle Component Analyses of Associations between Urinary
Microbiota and UTISA Symptoms. Figures depict principle component analysis (PCA)
plots for components 1 and 2 (PC1 & PC2) (A), for components 2 and 3 (PC2 & PC3)
(B), and for components 1, 2, and 3 (PC1 & PC2 & PC3) (C). The principle components
were calculated based on degree of association between the urinary microbiota and the
various symptoms (see Figure 19). The variance in the correlations between the
symptoms is maximized through each principle component. PC1 accounts for 34.35% of
the possible variance. PC2 accounts for 17.45% of the possible variance. PC3 accounts
for 16.25% of the possible variance. Together, PC1, PC2, and PC3 account for 68.05%
of the possible variance. The factor coefficients for the symptoms are: Frequency (0.262,
-0.418, -0.196), Urgency (0.165, -0.475, 0.326), Urinary Retention (0.206, -0.300, 0.419), Pelvic Pressure (0.289, 0.021, 0.195), Low Back Pain (0.202, 0.329, -0.547), Pain
or Burning (0.301, 0.425, 0.074), and Blood in the Urine (0.250, 0.198, 0.465).

CHAPTER V
CHARACTERIZING SELECT MICROORGANISMS
OF THE FUM
Introduction & Rationale
Knowing that the FUM is distinct between women with incontinence and the continent
controls (Chapter III), and that certain urinary microbiota have strong associations to
individual urinary symptoms (Chapter IV), the question arises: do these microorganisms
cause these symptoms and contribute to etiologies, or are they a result of the urinary
environment caused by the conditions? The data from Chapter III suggests that the FUM
is a result of the physical environment of the urogenital tract, whereas the data from
Chapter IV shows that the FUM is distinct across diverse unrelated urinary symptoms,
suggesting the opposite - that these microorganisms contribute to the various symptoms.
The most effective way to resolve this issue would be to introduce selected urinary bacterial
isolates or communities of bacterial isolates into an in vivo animal model and see if these
microorganisms alone induce symptoms. However, this approach would first require that
we characterize the urinary microbiota of that animal model, a time-consuming procedure
that we have just begun. It is also difficult to assess clinical urinary symptoms in an animal
model. Thus, the next best approach is to take an in vitro look at the ability of these
microorganisms to interact with one another and the host.
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FUM Interactions
To begin to assess the interactions of the microorganisms of the FUM, we analyzed the
likelihood that two microorganisms are co-cultured from the same urine sample (Figure
23). These data are presented in the form of a heat map. The microorganisms on both axes
are ordered from most cultured (S. anginosus – N=118) to least cultured. Only
microorganisms that have been cultured greater than or equal to 10 times are included in
the figure. The values for each pairing are based on the frequency with which they are cocultured together. The values on the x-axis (row) serve as the denominators for the
frequency calculations, while the values on the y-axis (variable) act as the numerators. The
data depicted come from a total of 497 EQUC-assessed TUC urine samples. 230 samples
come from Hilt et al., 2014 and Pearce et al., 2014. 124 samples come from Chapter III
and 118 samples come from Chapter IV. The final 52 samples come from unpublished
work on the maternal urinary microbiota. Of special interest are particular pairings with
high frequency scores and ones with low scores. A high frequency pairing (like
Streptococcus parasanguinis and Streptococcus mitis/oralis/pneumoniae – 86.67%) could
infer that these microorganisms create a microenvironment that is suitable for one another.
This could be important to know and understand because both microorganisms are also
statistically associated with the NO cohort in Chapter IV (Figure 15). Another interesting
pairing is one with low frequency scores. For example, E. coli and Lactobacillus crispatus
have a co-culture frequency score of just 3.17%. This could infer that these microorganisms
fill the same niche or that one directly or indirectly inhibits the other. This is a striking
relationship considering that E. coli is the most common cause of UTIs (Nicolle, 2008) and
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is strongly statistically associated with the YES cohort in Chapter IV (Figure 15), while
L. crispatus is statistically associated with healthy controls (Hilt et al., 2014), and shows
trending associations towards the continent controls in Chapter III. This suggests that there
may be a clinical significance behind this pairing.
Figure 24 looks at the same data set as Figure 23 but the values are represented as
correlations. A Pearson’s r Correlation value was calculated for each microorganismmicroorganism pairing. These correlation values assess the linear correlation between the
presence of one microorganism and the presence of the corresponding microorganism. The
values can range from -1 to 1, where negative values denote negative correlations, and
positive values denote the opposite. For this data set, correlation values greater than 0.088
or less than -0.088 are statistically significant (p<0.05). Since correlations consider the total
N for both microorganisms, the heat map of Figure 24 is a mirror image across the left-toright diagonal. The interesting pairing of L. crispatus and E. coli from Figure 23 has an rvalue of -0.0769 in Figure 24. This is one of the lowest correlations assessed in the entire
figure, yet it is not statistically significant [p=0.0863]. A major limitation of using
correlation values is that they consider the entire (N=497) data set. Consequently, for a
pairing to be completely correlated (r=1), both organisms would have to have been cultured
in every urine sample. This is not biologically rational and thus skews all of the data closer
to values of 0. Therefore, an r-score of -0.0769 (for the L. crispatus and E. coli pairing),
likely has physiological significance despite its lack of statistical significance.
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Figure 23. Heat Map of Co-Culture Frequencies of Urinary Microbiota Species. Coculture associations are displayed as “frequency (%)” - percentage of the time when the
microorganisms were culture, were they found together in the same sample. On both axes
are listed all the microorganisms cultured from various urine samples listed in order from
highest (bottom left) to lowest (top left, bottom right). Microorganisms cultured less than
10 times are not included. Frequencies are based on the number of times the
microorganism on the x-axis (row) was cultured. Data comes from a total of 497 urine
samples: 230 from Hilt et al, 2014, Pearce et al, 2014, unpublished work; 124 from Chapter
III; 118 from Chapter IV; and 52 from unpublished work on the maternal urinary
microbiota.
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Figure 24. Heat Map of Co-Culture Correlations of Urinary Microbiota Species. Coculture associations are displayed as “Correlations”. Correlations are calculated using
Pearson’s R. Values are scaled from scores 0.5 to -0.5. On both axes are listed all the
microorganisms cultured from various urine samples listed in order from highest (bottom
left) to lowest (top left, bottom right). Microorganisms cultured less than 10 times are not
included. Frequencies are based off of the number of times the microorganism on the xaxis (row) was cultured. Data comes from a total of 497 urine samples: 230 from Hilt et
al, 2014, Pearce et al, 2014, unpublished work; 124 from Chapter III; 118 from Chapter
IV; and 52 from unpublished work on the maternal urinary microbiota. Values greater than
or less than 0.088 are significant (p<0.05).
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Lactobacillus crispatus: A Potential Probiotic for E. coli UTIs
Lactobacilli are Gram-positive lactic acid-producing bacteria commonly residing in the
oral cavity, gastrointestinal tract, and the urogenital tract of mammals. Four species tend
to dominate the vaginal microbiome of young healthy women: L. iners, L. crispatus, L.
jensenii, and L. gasseri. Colonization of these microorganisms generally leads to a
protection from urogenital pathogens through a variety of known probiotic characteristics
including the production of lactic acid and hydrogen peroxide, strong adhesion to epithelial
cells, ability to modulate the host immune response, and production of bacteriocins and
antimicrobials (Ravel et al., 2010, Klebanoff et al., 1991, Ojala et al., 2014).
L. crispatus contributes to the stability of normal vaginal microbiota. Its absence
is linked to a variety of vaginal abnormalities, including BV. Certain strains of L. crispatus
are being tested as biotherapeutics for treatment of recurrent urinary tract infections (UTI)
in women (Stapleton et al., 2011). Additionally, cervicovaginal lavage (CVL) from
healthy women was shown to contain proteins that are bactericidal towards E. coli. Several
of these proteins correspond to L. crispatus (Kalyoussef et al., 2012).
16S rRNA Sequencing.
16S rRNA gene sequencing was performed on 10 urinary isolates of L. crispatus to
verify the MALDI-TOF MS identification as well as to determine the most closely related
strain. 8 of the chosen urinary isolates were from patients without any LUTS (Chapter III)
and Pearce et al., 2014), and 2 were from patients with UUI (Hilt et al., 2014, Pearce et al.,
2014). All 10 sequences were most closely related to strain ST1, one of 10 sequenced
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strains of L. crispatus (Ojala et al., 2014). Whereas 9 of the 10 sequenced strains are vaginal
isolates, ST1 is a GI isolate originally identified in an agricultural study of the crop (gut)
of chickens. This phylogenetic relationship leads to the hypothesis that the urinary isolates
detected by EQUC are quite distinct from known vaginal isolates and thus likely have
unique roles and characteristics.
In relation to E. coli, strain ST1 plays a potentially beneficial role. Strain ST1 has
been shown to be able to prevent the adherence and invasion of Enteropathogenic E. coli
(EPEC) to GI epithelial cells (Edelman et al., 2003, Edelman et al., 2012). This could
explain why urinary ST1-like urinary isolates of L. crispatus are not co-cultured with E.
coli.
Urothelial Cell Invasion Assay.
Using the protocol detailed in Figure 2, a ST1-like urinary isolate of L. crispatus
was competed with UPEC for its ability to competitively exclude UPEC from urothelial
cells. A non-malignant urothelial cell line (HURO23A) was used to assess binding. These
urothelial cells possess characteristics of both immature basal cells and mature superficial
urothelial cells (Le et al., 2014). Figure 25 shows that there was a significant drop in the
ability of UPEC to invade these cells in the presence of L. crispatus, but this difference
was only seen when the two microorganisms were added to the urothelial cells
simultaneously. The pre-treatment condition (in which L. crispatus was added 2 hours prior
to the UPEC) was not statistically different from the positive control. Thus, the urinary
ST1-like isolates of L. crispatus may protect urothelial cells from UPEC in a manner similar
to how the canonical ST1 strains protect gut epithelial cells from EPEC. More urinary
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strains of L. crispatus must be assessed to determine if this interaction is a general
characteristic of these microorganisms.
Competition Assays.
With the knowledge that L. crispatus and E. coli are not frequently co-cultured
(Figure 23), it is possible that there is an indirect or direct inhibition occurring between
the microorganisms (in addition to competitive exclusion of UPEC by L. crispatus). Since
L. crispatus is cultured more often in the non-LUTS control patients (Chapter III, Hilt et
al., 2014, Pearce et al., 2014), and E. coli is cultured more often in the YES (UTI) cohort
(Chapter IV), and with the knowledge that vaginal strains of L. crispatus may be protective
against E. coli colonization, it is possible that L. crispatus produces something that is
inhibitory towards E. coli.
To rapidly screen for inhibitory behavior, a lawn assay was performed (detailed in
Figure 3).There are several possible outcomes of this lawn assay. First, the lawn
microorganism might dominate. This would involve UPEC growing over the urinary
isolate. Second is co-existence of both. This would involve both UPEC and the urinary
isolate growing together. Last, the spotted organism might dominate. This could involve
the urinary isolate preventing UPEC preventing growth. UPEC strain CFT073 was used a
positive control, as it inhibits the growth of UPEC strain NU14.
Figure 26 shows that when a lawn of UPEC (NU14) was created, and a spot of L.
crispatus (cells or supernatant) was added, a zone of inhibition formed in which no UPEC
grew. This cannot be attributed to lactic acid or hydrogen peroxide (common metabolites
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of Lactobacillus) because when other species of Lactobacillus are assayed in the same
manner, there is no observable inhibition of UPEC growth despite the cultures having
identical pH (4.8-5.0). To verify this effect, spent culture supernatants (SCS) of various
Lactobacillus urinary isolates were added to an overnight culture of UPEC (NU14) in a 1:1
ratio and then assessed for UPEC viability over time (detailed in Figure 4). Figure 27
shows that the SCS of L. crispatus dramatically reduced UPEC viability within 2 hours of
incubation, while even after 24 hours, the SCS of L. gasseri and L. jensenii resulted in only
a mild reduction. As a control, the SCS of Gardnerella vaginalis (a non-lactic acid
producer) was tested; it resulted in no reduction in UPEC viability. Thus, the mild reduction
seen by L. gasseri and L. jensenii can likely be attributed to lactic-acid production, while
the large reduction see by L. crispatus cannot. Other urinary strains of L. crispatus have
been assessed and they affect UPEC differently; some result in complete killing of UPEC
by 2 hours, whereas others result in less killing.
Ethidium Bromide Assay.
To begin to assess how the L. crispatus SCS dramatically reduces the viability of
UPEC, an EtBr assay was performed. If EtBr can permeate the cell membrane of UPEC,
then it will bind the DNA, which can be detected by UV light. Thus, if a component of the
L. crispatus SCS acts to disrupt the membrane of UPEC, the EtBr will bind the DNA
(detailed in Figure 5). Indeed, Figure 28 shows that, after just 20 minutes, the L. crispatus
SCS induced UPEC EtBr binding at a level intermediate between the positive control (heatlysed UPEC) and the untreated negative control. Thus, it is likely that the inhibitory
component of the L. crispatus SCS acts as a pore to reduce the UPEC viability.
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Figure 25. UPEC Urothelial Cell Invasion in the Presence of L. crispatus Urinary
Isolates. The data are normalized to the amount of E. coli invasion in the UPEC alone
condition. There is statistical difference in UPEC invasion between the UPEC alone
condition and the L. crispatus + UPEC condition as assessed by a T-test for independent
samples (α=0.05) (* p<0.05; ** p<0.01).
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Figure 26. UPEC Lawn Inhibition by Lactobacillus Urinary Isolates. (Left) Growth of
L. crispatus on a lawn of UPEC (NU14) yields a distinct zone-of-clearance of the UPEC.
(Right) Growth of L. gasseri on a lawn of UPEC (NU14) yields no distinct zone-ofclearance of the UPEC. Assay was performed on TSA at 24 hours post-incubation in 5%
CO2, 37°C.
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Figure 27. UPEC Growth Inhibition by Urinary Isolates in Liquid Culture. The spent
culture supernatants of 3 different Lactobacilli and Gardnerella vaginalis (a non-lactic acid
producer) were added to an overnight culture of UPEC (NU14). The supernatants were
added in a 1:1 ratio. Cultures were incubated in aerobic, shaking environment. Timepoints
were taken at 0hrs (before supernatants added), 2hrs post-addition, and 24hrs post-addition.
The Media Control was MRS for the Lactobacilli, or TSB + 10% FBS for G. vaginalis. E.
coli growth was measured as CFU/mL by serially dilutions and plating on TSB and
incubating overnight in aerobic conditions. All samples have been repeated 3 times (3
separate isolates each tested once), with the exception of L. gasseri (twice) and G. vaginalis
(once).
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Figure 28. UPEC Susceptibility to EtBr after L. crispatus SCS treatment. (A). Positive
control; 100°C heat-lysed UPEC. (B). 1:1 addition of L. crispatus SCS. (C). Negative
control; media-treated UPEC. Image depicts EtBr DNA-binding visualized under UV light
after 20 minutes.
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Lactobacillus crispatus: Conclusions
Further experiments are needed to provide the necessary information to understand
how L. crispatus acts to kill UPEC. This refers to both the nature of the killing compound
as well as the specific mechanism of action of this compound towards UPEC. With this
knowledge, we can recommend the use of urinary isolates of L. crispatus as biotherapeutics
for E. coli UTIs. We can also use the purified compound as a targeted antimicrobial agent
against E. coli to treat UTIs. Nonetheless, these data show that the FUM does have a direct
impact on urinary health.

CHAPTER VI
DISCUSSION & CONCLUSIONS
It is clear from the presented data that the FUM likely plays a role in LUTS. This
knowledge is vital to the proper understanding of etiologies and treatments for these
various urinary symptoms and disorders.
In Chapter III, the data show that the FUM is distinct in diversity, genus-level
composition, and species-level composition between women with and without urinary
incontinence. Biodiversity assessed by the Shannon-Wiener Index show a markedly lower
diversity in the microorganism communities associated with continent women compared
to those of women with urinary incontinence. In terms of composition, A. schaalii, A.
turicensis, A. sanguinicola, A. urinae, and Corynebacterium lipophile group are all
statistically associated with the Incontinence cohort. Many of these microorganisms are
known or emerging uropathogens; therefore the idea that they may be a contributing factor
to the development of urinary incontinence is not unlikely. M. luteus was the only
microorganism associated with the Continence cohort suggesting that it may have a
beneficial role in urinary health and the prevention of incontinence. What that role might
be is unclear. The comparing of microbiota profiles highlights the dramatic difference in
diversity of the FUM between the two groups. This assessment also shows a large
difference in the number of EQUC-negative samples. Over a third of the samples from the
90
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Continence cohort were negative, whereas only about 10% of the samples from the
Incontinence cohort were negative. This highlights a major confounding factor to the
overall hypothesis that these microorganisms contribute to urinary symptoms. How could
this be true if there are patients with symptoms who potentially have no FUM? This
problem extends into Chapter IV as well, where there are some patients in the YES cohort
who are EQUC-negative despite their claim of severe urinary symptoms. There are a
couple possible explanations for this. First, there are large limitations using EQUC. The
EQUC conditions were developed to detect clinically relevant and commonly isolated
microorganisms. But even if these conditions were expanded, there are estimates as high
as 99% of naturally found microorganisms not being cultivatable using any known
techniques. It is very likely that the EQUC-negative patients are not devoid of a FUM. 16S
rRNA sequencing of urine samples shows that this is in part a valid explanation, as about
half of the EQUC-negative samples in a particular study were found to be sequencepositive (i.e. bacterial genomic DNA was detected) (Pearce et. al., 2014). Of the EQUC
and sequence-negative samples, there still may be a FUM present. As discussed earlier,
many of the urinary microorganisms are able to associate with urothelial cells (Khasriya et
al., 2013). Therefore, it is valid to assume that some of these physical associations will be
strong enough to prevent detachment during the urine voiding process, which would mean
that we cannot detect their presence by EQUC or sequencing in the TUC samples.
Unpublished data assessing the microorganism content of bladder urothelial cell biopsies
shows that there are microorganisms that are found solely attached to the tissue and are not
detected in TUC or SPA samples from the same individual. Whether these microorganisms
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are attached superficially to these urothelial cells or have been internalized is unclear.
Nonetheless, it can potentially account for the EQUC and/or sequence-negative samples.
Figure 9 of Chapter III details another important finding. This figure compares
the microbiota profiles of the Continence cohort from the data detailed in Chapter III with
that of data from Pearce et al., 2014. The resulting figure demonstrates a strong
reproducibility of data on the FUM. The two microbiota profiles are markedly similar in
terms of their genus-level composition. Additionally, the diversity and species-level
composition (data not shown) are also quite similar. This adds a degree of power to the rest
of the conclusions made throughout, because it shows that there is a high level of stability
to the data and little variation.
Collectively, the data comparing the FUM of women with and without urinary
incontinence suggests that the FUM may act to induce or prevent symptoms of urinary
incontinence through interactions with the host tissue. However, the data also show that
the FUM is not substantially different between subtypes of urinary incontinence (UUI and
SUI). This shows that the FUM may also be, in part, a result of the physical environment
of the urogenital tract. Women with either form of urinary incontinence have a wetter
urethra and vaginal tract due to the involuntary leakage. This could promote ease of
mobility for microorganisms to move between anatomical sites; it could also support the
growth of a unique population of microorganisms. Whether this in turn would exacerbate
symptoms is possible, yet unclear.
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As a follow up to the data from Chapter III, Chapter IV looks at FUM associations
with individual urinary symptoms, as opposed to an entire disorder, which may involve
numerous symptoms. FUM diversity and composition in a patient population with UTIlike symptoms (which are broad and diverse) (YES cohort) differed dramatically from
those in women with/without less severe UTI-like symptoms (NO cohort). These
differences included diversity and composition. The YES cohort was comprised of
communities of microorganisms with much lower biodiversity than that of the NO cohort.
In terms of composition, G. vaginalis, S. parasanguinis, and S. mitis/oralis/pneumoniae
were all found to be statistically associated with the NO cohort, while E. coli was strongly
associated with the YES cohort. The microbiota profiles highlight the strong differences in
diversity and composition.
The validated UTISA questionnaire was used to assess the associations between
individual urinary symptoms with species of the FUM. Use of this questionnaire and the
data from the original validation study (Clayson et al., 2005) also was used to show that
the NO cohort overall has statistically lower scores for severity and bother of the various
urinary symptoms. Therefore, the dramatic differences in diversity and composition of the
FUM between the cohorts can be directly connected to the degree of severity and bother of
the urinary symptom.
Each UTI symptom was found to be associated with a unique bacterial profile at
the species-level, in terms of degree of association, linear correlation, and covariance.
These associations were not as apparent at the genus-level composition or with respect to
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diversity of the FUM. These distinctions support the need to obtain species level
identification for deeper understanding of the relationship between the FUM and lower
urinary tract disorders.
In terms of associations between the FUM and the urinary symptoms, Figures 19
and 20 tell somewhat similar stories. Figure 19 looks at the associations in terms of how
often a given microorganism was cultured from a patient with a particular symptom,
whereas Figure 20 looks at the associations in terms of the correlation between having a
particular symptom and culturing a given microorganism. For some of the microorganisms,
the two figures tell the same story. For example, this could mean that a microorganism
associates and correlates highly with some of the seven symptoms. Therefore, not only is
that microorganism found often in samples where the patients have those symptoms, but
also out of all the patients with those symptoms, that microorganism is commonly found.
An example of this the uropathogen, Candida parapsilosis. C. parapsilosis is highly
associated and correlated with frequency and urinary retention. These data can be inferred
to mean that C. parapsilosis is likely directly contributing to the etiologies of those
symptoms. Conversely, there are microorganisms that associate highly with particular
symptoms, but do not correlate highly with them (or vice versa). An example of this is
Streptococcus anginosus. S. anginosus is highly associated with frequency and urgency,
and moderately associated with pelvic pain, and urinary retention (Figure 19), but it is
strongly negatively correlated with all of the urinary symptoms (Figure 20). Therefore, of
the patients with S. anginosus in their urine samples, quite a few of them have the four
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symptoms, but of all the patients with each of the four symptoms, less than half of them
had S. anginosus present. While this is a bit perplexing at first, it can actually be inferred
to mean that S. anginosus, while typically considered a uropathogen, is not directly causing
any of the symptoms, but rather it is commonly found with microorganisms that are
contributing to the symptoms. This is vital to understanding the pathophysiology of the
various urinary symptoms. S. anginosus may facilitate a microenvironment that is
conducive to the colonization of an organism that causes the symptoms. Therefore, in
determining proper treatment, the effects of S. anginosus must be considered. Furthermore,
this has strong implications for women with recurrent UTIs. It’s likely that organisms like
S. anginosus are facilitating repeated colonization of other uropathogens leading to
frequent infection. Proper treatment of recurrent UTIs likely will need to extend beyond
the primary pathogen involved in the infection.
Additionally, urinary symptoms seem to cluster into two distinct groups as assessed
by PCA. Frequency of urination, urgency of urination, and urinary retention vary less in
their associations with the FUM than the other four symptoms (pelvic pressure, pain and
burning during urination, lower back pain, and blood in the urine). This is an important
finding because it shows that potential bacterial etiologies of the clustered symptoms are
likely similar. This makes sense in the context of incontinence for example. Women with
UUI usually have symptoms of both urgency and frequency (OAB). Therefore, it is not
surprising that the FUM of women who have either urgency or frequency are similar.
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Unfortunately, many of these analyses did not consider CFU/mL of the cultured
microorganisms. Figure 21 shows that the CFU/mL of one microorganism (Enterococcus
faecalis) effects the degree of association with the various urinary symptoms. Generally,
the higher the CFU/mL, the higher the degree of association is with most of the symptoms.
Therefore, the size of a bacterium’s urinary population likely plays an integral role in
symptoms. One could imagine that higher CFU would allow for greater dissemination of
the bacteria throughout the bladder, allowing for greater potential impact on the host tissue
as well as the rest of the microflora. Higher CFUs could also allow for synergistic effects
of bacterial metabolites. Thus, CFU represents a substantial limitation to these findings and
should be included in future analyses.
It is important to consider that the NO cohort is not actually devoid of urinary
symptoms. In fact, much of this patient population has urinary incontinence. 47 patients of
the 75 were clinically diagnosed with incontinence. By looking at these select individuals
and comparing them to the Incontinence cohort (N=100) from Chapter III, one can assess
the reproducibility of the data. The microbiota profiles are quite similar to one another
(Figure S10) which shows consistency in the data. This is also important because it shows
again that there are distinct communities of microorganisms associated with the symptoms
of frequency and urgency that are different from other urinary symptoms.
Chapter V shows that one particular species of the FUM, L. crispatus, can impact
symptoms. This organism is able to directly exclude and inhibit UPEC, which is known to
cause the majority of UTIs and is clinically manifested as several urinary symptoms. This
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inhibition occurs on urothelial cells in vitro, on solid media, and in liquid culture. The
nature of the compound as well as the mechanism of action are unclear at this point.
However, the data show that the compound is likely acting on the cell membrane of UPEC
in a manner that is similar to antimicrobial peptides. Nonetheless, it is critical to follow up
on these data and identify and characterize this compound. By introducing L. crispatus into
the bladder environment as a probiotic or by introducing the compound as an antimicrobial,
clinicians could potentially limit the growth and colonization of UPEC. This could act to
cure several urinary symptoms brought on by UPEC, as well as to prevent recurrent
infections.
Interestingly, the urinary isolates of L. crispatus that were sequenced were more
closely related to a gut strain of L. crispatus (ST1) than to any known vaginal strains. This
is rather striking considering the close proximity of the bladder and vagina. One might
expect frequent microbial sharing between environments during voiding. Therefore, this
finding shows that the urinary isolates are evolutionarily distinct from vaginal isolates (at
least for L. crispatus). This immensely supports the notion that the microbiota of the
bladder and vagina are distinct, not only in composition but also in their roles in urinary
health and symptoms. This also shows that urinary microorganisms can potentially have
vastly distinct and unique characteristics.
To conclude, with the knowledge presented in this discussion, we can now start to
make directed hypotheses towards understanding whether some of the associations
between the FUM and the symptoms are physiologically relevant, in terms of
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understanding the process and mechanisms behind those associations as well as how to
intervene to prevent and treat them more effectively. The possibilities are limitless for how
the microbiota could influence various symptoms, but it is clear at this point that they are
able to, and these interactions may be vital to fully understanding lower urinary tract
symptoms.

APPENDIX A:
DEVELOPING AN OPTIMAL
URINE CULTURE PROTOCOL
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Introduction & Rationale
Since the 1950’s, the clinical practice for detecting infection in the bladder, including
cystitis (bladder infection) and pyelonephritis (kidney infection), has been based on the
detection of ≥105 CFU/mL of a known uropathogen, using the standard urine culture
protocol. This method was actually established to detect the patients that were likely
susceptible to pyelonephritis (Kass, 1956). The method has since been adopted to include
lower urinary tract infections as well, despite any empirical evidence that this was valid.
Thus, many studies have provided evidence that this threshold of ≥105 is insufficient to
detect significant bladder infection (Stamm et al., 1982, Stark et al., 1984, Lipsky et al.,
1987, Thomas et al., 2013). For example, many women present with some or all of the
symptoms of a urinary tract infection, but their standard urine culture is deemed “NO
GROWTH”. At this juncture, the patient is informed that they do not have a UTI. These
patients are not given antibiotics and thus in many cases their symptoms persist. In rare
cases, the urinary infection can lead to systemic life-threatening infections.
Using the EQUC protocol, bacteria can be detected in 70-90% of the urines that
were deemed “NO GROWTH” by standard culture (85.71% - Chapter III, 70.37% Chapter IV). Even in women who feel they have a UTI (Chapter IV), the false negative
rate for standard culture was 35.00%. As assessed by EQUC, the standard protocol misses
known or emerging uropathogens present in the urine of many individuals. These bacteria
may be clinically relevant to the patients’ symptoms. To develop an optimal urine culture
protocol for detection of clinically relevant microorganisms that we could recommend to
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the clinical microbiology community, we analyzed the data obtained from the patient
population described in Chapter IV using the study outline from Figure 11.
UTI Study: A New Urine Culture Protocol
Overview of Study.
This study uses the same patient population and design as the study discussed in
Chapter IV. Figure 11 details the study outline. The TUC urine specimens that were
collected from the 118 women were assessed for bacterial growth using the standard urine
culture protocol as well as the expanded EQUC protocol (Table 1). The expanded EQUC
protocol adds MacConkey agar and Campy gas mixture to the original EQUC protocol
(Hilt et al., 2014). MacConkey agar is ideal for the growth of typical uropathogens and is
already used as part of the standard urine culture protocol. MacConkey agar also allows
for quick phenotypic analysis of the bacterial growth based on the ability to ferment lactose.
The Campy gas mixture provides an optimal environment for the isolation of fecal
contaminant microorganisms. Additionally, three volumes of urine (1µL, 10µL, and
100µL) were used for each expanded EQUC, for a total of 21 plates (Table 1). This allows
for the determination of an optimal protocol.
The standard urine culture was performed by the Clinical Microbiology Laboratory
staff at Loyola University Medical Center. All patient care was a consequence of the results
of the standard culture alone. The expanded EQUC results were not reported and thus did
not impact patient care. In December 2014, the Clinical Microbiology Laboratory began
using the modified urine culture protocol (Table 1). This change affected patient study
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ID’s 108-118. All data obtained for this study, was from combining the data obtained from
the use of all three urine volumes of the expanded EQUC protocol at the 48 hour timepoint
unless stated otherwise.
After 48 hours of incubation in the respected environmental conditions, the various
plates were documented for morphologies and sub-cultured. The pure cultures were
identified using MALDI-TOF MS, and were stored at -80°C for future study.
Determining an Optimal Protocol.
As expected, the greater the volume of urine plated, the greater the number of
unique microorganisms were detected. These data are depicted in Figure A1, which
presents them in the form of rarefaction curves. After 118 urine samples assessed (both the
YES and NO cohorts), standard/modified urine culture detected 8 unique species. The 1µL
expanded EQUC detected 31 unique species. This is rather striking considering that both
protocols involve plating the same volume of urine, yet the expanded EQUC detected over
four times more unique species. This demonstrates the power of using other environmental
conditions and holding the plates for longer periods of time. The 10µL expanded EQUC
detected 48 unique species, and the 100µL protocol detected 82 unique species. (Figure
A1). Statistical analyses support the dramatic differences in diversity. Using the Shannon
Diversity Index, the 100µL protocol had a high measure of biodiversity (3.862) while the
standard culture had a much lower measure (1.169). The other protocols fell in an
intermediate range (1µL – 2.879, 10µL – 3.393).

[103]

Figure A1. Rarefaction Analysis of Various Urine Culture Protocols. The
Standard/Modified Urine Culture protocol (N=118) contains 8 unique species and is
depicted by the blue circles. The 1µL Expanded EQUC protocol (N=118) contains 31
unique species and is depicted by the red squares. The 10µL Expanded EQUC protocol
(N=118) contains 48 unique species and is depicted by the green diamonds. The 100µL
Expanded EQUC protocol (N=118) contains 82 unique species and is depicted by the
purple triangles.
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Despite the dramatic difference in total number of unique species between
protocols, not all of these microorganisms are currently understood to be clinically relevant
(though they may be). Table A1 looks at just the microorganisms known to be clinically
relevant (known and emerging uropathogens) and the differences in their detection between
the protocols.18 known and emerging uropathogens were detected 126 times in this patient
population: Actinobaculum schaalii (N=5), Aerococcus urinae (N=11), Alloscardovia
omnicolens (N=6), Candida albicans (N=2), Candida parapsilosis (N=4), Citrobacter
koseri (N=1), Corynebacterium riegelii (N=3), Corynebacterium urealyticum (N=1),
Enterobacter aerogenes (N=3), Enterococcus faecalis (N=12), Escherichia coli (N=25),
Klebsiella pneumoniae (N=8), Proteus mirabilis (N=1), Pseudomonas aeruginosa (N=1),
Serratia marcescens (N=1), Staphylococcus aureus (N=6), Streptococcus agalactiae
(N=10), and Streptococcus anginosus (N=26). The 100µL expanded EQUC protocol
detected 94% (119/126) of the total uropathogens. This value is not 100% because
occasionally, a microorganism cultured at a high CFU/mL will overwhelm the plates on
the 100µL protocol, and thus some uropathogens are actually missed. So a higher volume
of urine is not always the best option. The 10µL expanded EQUC protocol detected 58%
(73/126) of the total uropathogens. The 1µL expanded EQUC protocol detected 45%
(57/126) of the total uropathogens. The standard/modified urine culture protocol detected
only 26% (33/126) of the total uropathogens. Table A1 summarizes these data.
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Table A1. Overview of Uropathogen Detection by Various Urine Culture Protocols.
(top) On the left are the various urine culture protocols. In the middle column are the
percentage of uropathogens detected by the corresponding protocol. Out of the 118
patients, 126 uropathogens were detected. In the right column are the percentage of urine
samples or patients where at least one uropathogen was detected by the corresponding
protocol. 78 out of the 118 patients had uropathogens detected. (bottom) Listed are all of
the detected known and emerging uropathogens. In parentheses are the number of times
that microorganism was detected by the Standard/Modified Urine Culture protocol over
the number of times that microorganism was detected by any of the Expanded EQUC
protocols.
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From the YES cohort only, 54 uropathogens were detected in 43 patients. 96%
(52/54) were detected with the 100µL protocol, 74% (40/54) were detected with the 10µL
protocol, 69% (37/54) were detected with the 1µL protocol, and 52% (28/54) were detected
by the standard/modified culture. These values, while much higher than those obtained for
the entire patient population, are dramatically skewed by the detection of E. coli. For
example, standard/modified culture detected E. coli in all 18 YES cohort samples that had
E. coli detected by expanded EQUC. This means that the standard/modified culture
protocol only detected 10 of the remaining 36 uropathogens (28%) that were detected by
expanded EQUC in the YES cohort. In fact, when looking at the entire patient population,
standard/modified culture detected 92% (23/25) of the E. coli, but only 10% (10/101) of
the non-E. coli uropathogens.
As alluded to in Chapter IV, the CFU/mL with which a microorganism is cultured
likely plays a clinical role (Figure 21). This is the basic idea behind using ≥105 as a
threshold for infection; however, this threshold appears to be ineffective as assessed by the
data from this study. Figure A2 depicts the average CFU/mL with which the various
uropathogens were detected in either cohort (YES and NO). It appears that for the majority
of the uropathogens, the average CFU/mL was higher in the YES cohort than the NO,
suggesting that when an individual has UTI-like symptoms, the presence of a uropathogen
was at a higher CFU than an individual who does not have symptoms (or less severe).
When the ≥105 CFU/mL threshold for infection is used, it does not do a good job capturing
any uropathogens.
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Figure A2. Average CFU/mL of Uropathogens between YES and NO Cohorts. The
YES cohort (N=43) is depicted by the blue bars, and the NO cohort (N=75) is depicted by
the red bars. Depicted are the average CFU/mL with which the various uropathogens were
cultured for both cohorts. Two lines are drawn in to represent commonly used clinical
thresholds for UTI diagnosis (≥105 CFU/mL and ≥103 CFU/mL).
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Even the lower threshold of ≥103 CFU/mL (a common threshold for catheterized urine
samples) is ineffective. This threshold captured uropathogens, but some of these are in the
NO cohort, and some uropathogens in the YES cohort were still missed. Thus, the use of
one threshold for all infections is not appropriate. Diagnosis of UTI must be on a personby-person basis and thresholds should be established for each uropathogen. For example,
these data suggest that >100 CFU/mL of Aerococcus urinae is indicative of clinical
infection/symptoms, but <100 CFU/mL is not. However, the idea of a species-specific
threshold would not work for E. coli, which appears to be at equivalent average CFU/mL
between the two cohorts. In the case of E. coli, the problem rests with the inability to
distinguish UPEC and asymptomatic bacteriuria (ABU) strains, which are close relatives.
However, it is important to consider that the NO cohort is not necessarily devoid of urinary
symptoms.
When looking at the seven different plating conditions, there also exists
large differences in their abilities to detect microorganisms and specifically uropathogens.
Figure A3 represents a rarefaction analysis used to assess the differences in the number of
unique species detected by each plating condition. It seems that BAP incubated in 5% CO2
and the CDC anaerobe 5% sheep blood agar plate incubated anaerobically detected the
highest number of unique species, 52. The Campy condition, CNA and Chocolate agar in
5% CO2 all detected intermediate numbers of unique species (48, 45, 43 respectively).
Interestingly, the two conditions that comprise the Standard Urine Culture protocol (BAP
and MacConkey – aerobic incubation) detected the least number of unique species (36 and

[109]

6 respectively). These data come from a combination of the expanded EQUC protocols and
represent the 48 hour timepoint data.
Looking at cultivation of uropathogens between the various culturing conditions,
there also exists large differences. Table A2 lists the total number of each uropathogen
detected in the various culturing conditions. BAP in 5% CO2, CNA in 5% CO2, and
Anaerobic BAP incubated anaerobically, detected the greatest number of uropathogens.
Together, they are able to detect each uropathogen individually. At 100µL of urine, held
for 48 hours, these plates would have detected 87% (109/126) of the total uropathogens
and 89% (48/54) of the uropathogens from the patients in the YES cohort. However,
implementation of an anaerobic condition for urine cultures is not necessarily feasible for
clinical microbiology laboratories. Thus, an optimal and feasible urine culture would be
BAP, CNA, and MacConkey in 5% CO2. Despite the low levels of detection of
uropathogens by MacConkey agar (aerobically), this medium allows for phenotypic
distinctions between morphologies, which is particularly useful in diagnosing E. coli and
Klebsiella pneumoniae infections (the two most common uropathogens). Using 100µL of
urine and holding for 48 hours in 5% CO2 for these plates would have resulted in 79%
(99/126) total uropathogen detection, and 87% (47/54) uropathogen detection in the YES
cohort. These data stem from of holding the MacConkey agar in aerobic conditions. It is
unclear how much of a difference incubating in 5% CO2 will make.
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Figure A3. Rarefaction Analysis of Various Urine Culture Plating Conditions. The
BAP in 5% CO2 condition group contains 52 unique species and is depicted by the blue
circles. The Chocolate agar in 5% CO2 condition group contains 43 unique species and is
depicted by the red squares. The CNA in 5% CO2 condition group contains 45 unique
species and is depicted by the green diamonds. The Anaerobic BAP incubated
anaerobically group contains 52 unique species and is depicted by the purple triangles. The
BAP incubated aerobically group contains 36 unique species and is depicted by the blue
x’s. The MacConkey agar incubated aerobically group contains 6 unique species and is
depicted by the orange pluses. The Anaerobic BAP incubated in a Campy environment
group contains 48 unique species and is depicted by the dark blue dashes.
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To conclude, it is clear from these data, that current methods and interpretation of
data using the standard urine culture protocol are overwhelmingly inefficient. We
recommend adopting the optimal urine culture protocol detailed above, as well as a
reconsideration of the current thresholds for UTI diagnosis.
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Table A2. Overview of Plating Conditions for Detection of Uropathogens. Depicted
are a list of the uropathogens and the number of times each was cultured by the various
culturing conditions.

APPENDIX B:
SUPPLEMENTAL FIGURES
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Figure S1. Frequency of Species in UUI, SUI, & Continence Cohorts. The SUI cohort (N=50)
is depicted by the blue bars, the UUI cohort (N=50) is depicted by the orange bars, and the
Continence Cohort (N=24) is depicted by the grey bars.
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Figure S2. Microbiota Profiles of Incontinence & Continence Cohorts. Depicts the genuslevel microbiota composition based on percent CFU/mL urine for the given patient urine sample.
The Continence cohort combines data from Chapter III and from Pearce et al., 2014 (bottom) and
contains 75 urine samples. The Incontinence cohort combines the UUI and SUI cohorts (top) and
contains 100 urine samples. The figures have been stretched to be equivalent sizes for better
qualitative comparisons.
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Figure S3. Frequency of Species in Incontinence & Continence Cohorts. The Incontinence
cohort (N=100) is depicted by the blue bars and the Continence cohort (N=75) is depicted by the
orange bars.
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Figure S4. Frequency of Species in the YES & NO Cohorts. The YES cohort (N=43) is depicted
by the blue bars and the NO cohort (N=75) is depicted by the red bars.
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Figure S5. Microbiota Profiles of Incontinence Cohorts. Depicts the genus-level microbiota
composition based on percent CFU/mL urine for the given patient urine sample. The Incontinence
(UUI & SUI) cohort from Chapter III (top) contains 100 urine samples. The NO Cohort from
Chapter IV (bottom) contains 47 urine samples from individuals within the NO Cohort (N=75)
who also had urinary incontinence. The figures have been stretched to be equivalent sizes for better
qualitative comparisons.
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